Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• 'Deep Koebner' phenomenon of the flexor tendon-associated accessory pulleys as a novel factor in tenosynovitis and dactylitis in psoriatic arthritis.1 passage
• 'Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study' by Moltó1 passage
• 'Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki1 passage
• 'SMASH' recommendations for standardised microscopic arthritis scoring of histological sections from inflammatory arthritis animal models.1 passage
• 'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients'.1 passage
• (untitled)4 passages
• 10-Year natural course of early hip osteoarthritis in middle-aged persons with hip pain: a CHECK study.1 passage
• 14-3-3 epsilon is an intracellular component of TNFR2 receptor complex and its activation protects against osteoarthritis.1 passage
• 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations.1 passage
• 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.1 passage
• 2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative.1 passage
• 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.1 passage
• 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.1 passage
• 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.1 passage
• 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.1 passage
• 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.1 passage
• 2016 update of the EULAR recommendations for the management of early arthritis.1 passage
• 2016 update of the EULAR recommendations for the management of rheumatoid arthritis: a utopia beyond patients in low/middle income countries?1 passage
• 2016 updated EULAR evidence-based recommendations for the management of gout.1 passage
• 2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis.1 passage
• 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups.1 passage
• 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis.1 passage
• 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis.1 passage
• 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.1 passage
• 2018 update of the EULAR recommendations for the management of Behçet's syndrome.1 passage
• 2018 update of the EULAR recommendations for the management of hand osteoarthritis.1 passage
• 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis.1 passage
• 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout.1 passage
• 2019 EULAR points to consider for non-physician health professionals to prevent and manage fragility fractures in adults 50 years or older.1 passage
• 2019 EULAR points to consider for the assessment of competences in rheumatology specialty training.1 passage
• 2019 EULAR recommendations for the generic core competences of health professionals in rheumatology.1 passage
• 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus.1 passage
• 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis.1 passage
• 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.1 passage
• 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.1 passage
• 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice.1 passage
• 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis.1 passage
• 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.1 passage
• A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.1 passage
• A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).1 passage
• A WHO Reference Reagent for lupus (anti-dsDNA) antibodies: international collaborative study to evaluate a candidate preparation.1 passage
• A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment.1 passage
• A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythematosus.1 passage
• A deletion at ADAMTS9-MAGI1 locus is associated with psoriatic arthritis risk.1 passage
• A family-based genome-wide association study reveals an association of spondyloarthritis with MAPK14.1 passage
• A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS).1 passage
• A gain of function mutation in TNFRSF11B encoding osteoprotegerin causes osteoarthritis with chondrocalcinosis.1 passage
• A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study.1 passage
• A genome-wide association study of rheumatoid arthritis without antibodies against citrullinated peptides.1 passage
• A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.1 passage
• A homeostatic function of CXCR2 signalling in articular cartilage.1 passage
• A key role for Fut1-regulated angiogenesis and ICAM-1 expression in K/BxN arthritis.1 passage
• A longitudinal study of the association between infrapatellar fat pad maximal area and changes in knee symptoms and structure in older adults.1 passage
• A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.1 passage
• A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.1 passage
• A new autoinflammatory and autoimmune syndrome associated with NLRP1 mutations: NAIAD (1 passage
• A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever.1 passage
• A novel evidence-based detection of undiagnosed spondyloarthritis in patients presenting with acute anterior uveitis: the DUET (Dublin Uveitis Evaluation Tool).1 passage
• A novel method for bone area measurement provides new insights into osteoarthritis and its progression.1 passage
• A novel variant in1 passage
• A patient-initiated DMARD self-monitoring service for people with rheumatoid or psoriatic arthritis on methotrexate: a randomised controlled trial.1 passage
• A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.1 passage
• A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy.1 passage
• A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study.1 passage
• A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.1 passage
• A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.1 passage
• A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.1 passage
• A psychometric analysis of outcome measures in peripheral spondyloarthritis.1 passage
• A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout.1 passage
• A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis.1 passage
• A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate.1 passage
• A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.1 passage
• A randomised trial of a brace for patellofemoral osteoarthritis targeting knee pain and bone marrow lesions.1 passage
• A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis.1 passage
• A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.1 passage
• A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis.1 passage
• A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab.1 passage
• A rare coding allele in1 passage
• A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker.1 passage
• A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers.1 passage
• A single nucleotide polymorphism in the1 passage
• A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.1 passage
• A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.1 passage
• A unique circulating miRNA profile highlights thrombo-inflammation in Behçet's syndrome.1 passage
• A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk.1 passage
• A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease.1 passage
• ACPA IgG galactosylation associates with disease activity in pregnant patients with rheumatoid arthritis.1 passage
• ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study.1 passage
• ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.1 passage
• AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis.1 passage
• Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial.1 passage
• Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease.1 passage
• Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors.1 passage
• Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.1 passage
• Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.1 passage
• Activated T cells enhance interferon-α production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes.1 passage
• Activated human B cells induce inflammatory fibroblasts with cartilage-destructive properties and become functionally suppressed in return.1 passage
• Activation of acid-sensing ion channel 3 by lysophosphatidylcholine 16:0 mediates psychological stress-induced fibromyalgia-like pain.1 passage
• Activation of liver X receptors inhibits experimental fibrosis by interfering with interleukin-6 release from macrophages.1 passage
• Acute coronary syndrome in new-onset rheumatoid arthritis: a population-based nationwide cohort study of time trends in risks and excess risks.1 passage
• Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms.1 passage
• Acyltransferase skinny hedgehog regulates TGFβ-dependent fibroblast activation in SSc.1 passage
• Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study.1 passage
• Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial.1 passage
• Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.1 passage
• Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis.1 passage
• Additional comment to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Scherlinger and Schaeverbeke.1 passage
• Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases: comment on 'Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative' by Baillet et al.1 passage
• Additional response to the correspondence: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Bennuci.1 passage
• Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.1 passage
• Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis.1 passage
• Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.1 passage
• Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.1 passage
• Agrin mediates chondrocyte homeostasis and requires both LRP4 and α-dystroglycan to enhance cartilage formation in vitro and in vivo.1 passage
• Aicardi-Goutières syndrome harbours abundant systemic and brain-reactive autoantibodies.1 passage
• Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes.1 passage
• Alarmins S100A8/S100A9 aggravate osteophyte formation in experimental osteoarthritis and predict osteophyte progression in early human symptomatic osteoarthritis.1 passage
• All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013).1 passage
• Allopurinol and the risk of atrial fibrillation in the elderly: a study using Medicare data.1 passage
• Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study.1 passage
• Allopurinol initiation and all-cause mortality in the general population.1 passage
• Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra.1 passage
• Altered DNA methylation in children born to mothers with rheumatoid arthritis during pregnancy.1 passage
• Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes.1 passage
• Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.1 passage
• Among human macrophages polarised to different phenotypes, the M-CSF-oriented cells present the highest pro-inflammatory response to the rheumatoid arthritis-specific immune complexes containing ACPA.1 passage
• Amount of smoking, duration of smoking cessation and their interaction with silica exposure in the risk of rheumatoid arthritis among males: results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis (EIRA) study.1 passage
• An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS.1 passage
• An OMERACT reliability exercise of inflammatory and structural abnormalities in patients with knee osteoarthritis using ultrasound assessment.1 passage
• An ankylosing spondylitis-associated genetic variant in the IL23R-IL12RB2 intergenic region modulates enhancer activity and is associated with increased Th1-cell differentiation.1 passage
• An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.1 passage
• An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial.1 passage
• An induction or flare of arthritis and/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series.1 passage
• Analysis of distribution and severity of inflammation in patients with osteoarthitis compared to rheumatoid arthritis by ICG-enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study.1 passage
• Analysis of periarticular bone changes in patients with cutaneous psoriasis without associated psoriatic arthritis.1 passage
• Angiogenic T cells are decreased in rheumatoid arthritis patients.1 passage
• Ankylosing spondylitis and risk of ischaemic heart disease: a population-based cohort study.1 passage
• Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?1 passage
• Anti-Ku syndrome with elevated CK and anti-Ku syndrome with anti-dsDNA are two distinct entities with different outcomes.1 passage
• Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.1 passage
• Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.1 passage
• Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.1 passage
• Anti-TNFα agents curb platelet activation in patients with rheumatoid arthritis.1 passage
• Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease.1 passage
• Anti-centromere antibodies target centromere-kinetochore macrocomplex: a comprehensive autoantigen profiling.1 passage
• Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis.1 passage
• Anti-inflammatory effects of cell-based therapy with tyrosine hydroxylase-positive catecholaminergic cells in experimental arthritis.1 passage
• Anti-inflammatory therapy for COVID-19 infection: the case for colchicine.1 passage
• Antibodies against carbamylated proteins are present in primary Sjögren's syndrome and are associated with disease severity.1 passage
• Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications.1 passage
• Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars.1 passage
• Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis.1 passage
• Antibody-mediated inhibition of syndecan-4 dimerisation reduces interleukin (IL)-1 receptor trafficking and signalling.1 passage
• Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.1 passage
• Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients.1 passage
• Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts.1 passage
• Anticitrullinated protein antibodies facilitate migration of synovial tissue-derived fibroblasts.1 passage
• Anticitrullinated protein/peptide antibody multiplexing defines an extended group of ACPA-positive rheumatoid arthritis patients with distinct genetic and environmental determinants.1 passage
• Anticollagen type II antibodies are associated with an acute onset rheumatoid arthritis phenotype and prognosticate lower degree of inflammation during 5 years follow-up.1 passage
• Antifibrotic factor KLF4 is repressed by the miR-10/TFAP2A/TBX5 axis in dermal fibroblasts: insights from twins discordant for systemic sclerosis.1 passage
• Antigen-driven selection of antibodies against SSA, SSB and the centromere 'complex', including a novel antigen, MIS12 complex, in human salivary glands.1 passage
• Antimodified protein antibody response pattern influences the risk for disease relapse in patients with rheumatoid arthritis tapering disease modifying antirheumatic drugs.1 passage
• Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco1 passage
• Aortic-vertebral interaction in ankylosing spondylitis: syndesmophyte development at the juxta-aortic vertebral rim.1 passage
• Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis.1 passage
• Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus.1 passage
• Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease.1 passage
• Applying cascaded convolutional neural network design further enhances automatic scoring of arthritis disease activity on ultrasound images from rheumatoid arthritis patients.1 passage
• Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).1 passage
• Are MRI-detected erosions specific for RA? A large explorative cross-sectional study.1 passage
• Are allopurinol dose and duration of use nephroprotective in the elderly? A Medicare claims study of allopurinol use and incident renal failure.1 passage
• Are corticosteroid injections needed after needling and lavage of calcific tendinitis? Randomised, double-blind, non-inferiority trial.1 passage
• Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?1 passage
• Arterial haemodynamics and coronary artery calcification in adult patients with juvenile idiopathic arthritis.1 passage
• Arthroscopic partial meniscectomy versus placebo surgery for a degenerative meniscus tear: a 2-year follow-up of the randomised controlled trial.1 passage
• Articular chondrocyte network mediated by gap junctions: role in metabolic cartilage homeostasis.1 passage
• Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.1 passage
• Assessment of disease activity in patients with rheumatoid arthritis using optical spectral transmission measurements, a non-invasive imaging technique.1 passage
• Assessment of fluorinated steroids to avert progression and mortality in anti-SSA/Ro-associated cardiac injury limited to the fetal conduction system.1 passage
• Association between MRI-detected knee joint regional effusion-synovitis and structural changes in older adults: a cohort study.1 passage
• Association between bisphosphonate use and risk of undergoing knee replacement in patients with osteoarthritis.1 passage
• Association between childhood overweight measures and adulthood knee pain, stiffness and dysfunction: a 25-year cohort study.1 passage
• Association between inactivated influenza vaccine and primary care consultations for autoimmune rheumatic disease flares: a self-controlled case series study using data from the Clinical Practice Research Datalink.1 passage
• Association between rheumatoid arthritis disease activity, progression of functional limitation and long-term risk of orthopaedic surgery: combined analysis of two prospective cohorts supports EULAR treat to target DAS thresholds.1 passage
• Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry.1 passage
• Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome.1 passage
• Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis.1 passage
• Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at-risk individuals.1 passage
• Association of chemokine CXC ligand 12 gene polymorphism (rs1746048) with cardiovascular mortality in patients with rheumatoid arthritis: results from the Norfolk Arthritis Register.1 passage
• Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.1 passage
• Association of novel rare coding variants with juvenile idiopathic arthritis.1 passage
• Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for1 passage
• Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou1 passage
• Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis.1 passage
• Association of the1 passage
• Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis.1 passage
• Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.1 passage
• Associations of regular glucosamine use with all-cause and cause-specific mortality: a large prospective cohort study.1 passage
• Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment.1 passage
• Attenuating the mortality risk of high serum uric acid: the role of physical activity underused.1 passage
• Autoantibodies and scleroderma phenotype define subgroups at high-risk and low-risk for cancer.1 passage
• Autoantibodies targeting telomere-associated proteins in systemic sclerosis.1 passage
• Autoimmune diseases in Adult Life after Childhood Cancer in Scandinavia (ALiCCS).1 passage
• Autologous stem cell transplantation leads to a change in proinflammatory plasma cytokine profile of patients with juvenile dermatomyositis correlating with disease activity.1 passage
• Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.1 passage
• Automated squeeze test (Gaenslen's manoeuvre) to identify patients with arthralgia suspicious for progression to RA: improving time delay to rheumatology consultation.1 passage
• Autophagy is activated in systemic lupus erythematosus and required for plasmablast development.1 passage
• Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.1 passage
• Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine.1 passage
• Axial spondyloarthritis.1 passage
• B cell depletion impairs vaccination-induced CD81 passage
• B cell resistance to Fas-mediated apoptosis contributes to their ineffective control by regulatory T cells in rheumatoid arthritis.1 passage
• B cell subset composition segments clinically and serologically distinct groups in chronic cutaneous lupus erythematosus.1 passage
• B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease.1 passage
• B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial.1 passage
• BCP crystals promote chondrocyte hypertrophic differentiation in OA cartilage by sequestering Wnt3a.1 passage
• BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus.1 passage
• BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease.1 passage
• Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis.1 passage
• Back to the future: forget ultrasound and focus on clinical assessment in rheumatoid arthritis management.1 passage
• Bacterial citrullinated epitopes generated by1 passage
• Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.1 passage
• Baseline predictors of different types of treatment success in rheumatoid arthritis.1 passage
• Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA).1 passage
• Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases.1 passage
• Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.1 passage
• Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis.1 passage
• Biological stress systems, adverse life events and the onset of chronic multisite musculoskeletal pain: a 6-year cohort study.1 passage
• Biomarker-related risk for myocardial infarction and serious infections in patients with rheumatoid arthritis: a population-based study.1 passage
• Biomechanical properties of bone are impaired in patients with ACPA-positive rheumatoid arthritis and associated with the occurrence of fractures.1 passage
• Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis.1 passage
• Blocking interferon γ reduces expression of chemokines CXCL9, CXCL10 and CXCL11 and decreases macrophage infiltration in ex vivo cultured arteries from patients with giant cell arteritis.1 passage
• Blood-based test for diagnosis and functional subtyping of familial Mediterranean fever.1 passage
• Blood-brain barrier leakage in systemic lupus erythematosus is associated with gray matter loss and cognitive impairment.1 passage
• Bone marrow lesions and synovitis on MRI associate with radiographic progression after 2 years in hand osteoarthritis.1 passage
• Breach of autoreactive B cell tolerance by post-translationally modified proteins.1 passage
• Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.1 passage
• Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.1 passage
• Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015.1 passage
• Burden of musculoskeletal disorders in the Eastern Mediterranean Region, 1990-2013: findings from the Global Burden of Disease Study 2013.1 passage
• CCL2/CCR2, but not CCL5/CCR5, mediates monocyte recruitment, inflammation and cartilage destruction in osteoarthritis.1 passage
• CD109 regulates the inflammatory response and is required for the pathogenesis of rheumatoid arthritis.1 passage
• CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritis.1 passage
• COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco1 passage
• CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up.1 passage
• Call for action in ANCA-associated vasculitis and lupus nephritis: promises and challenges of SGLT-2 inhibitors.1 passage
• Call for emergency action to limit global temperature increases, restore biodiversity and protect health.1 passage
• Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.1 passage
• Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?1 passage
• Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' by Joob and Wiwanitkit.1 passage
• Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease.1 passage
• Can we use structural lesions seen on MRI of the sacroiliac joints reliably for the classification of patients according to the ASAS axial spondyloarthritis criteria? Data from the DESIR cohort.1 passage
• Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.1 passage
• Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.1 passage
• Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome.1 passage
• Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study.1 passage
• Cancer risk in patients with spondyloarthritis treated with TNF inhibitors: a collaborative study from the ARTIS and DANBIO registers.1 passage
• Candidate lesion-based criteria for defining a positive sacroiliac joint MRI in two cohorts of patients with axial spondyloarthritis.1 passage
• Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis.1 passage
• Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity.1 passage
• Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis.1 passage
• Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment.1 passage
• Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data.1 passage
• Cartilage-specific deletion of mTOR upregulates autophagy and protects mice from osteoarthritis.1 passage
• Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome.1 passage
• Central reader evaluation of MRI scans of the sacroiliac joints from the ASAS classification cohort: discrepancies with local readers and impact on the performance of the ASAS criteria.1 passage
• Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus.1 passage
• Certain class I HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype.1 passage
• Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.1 passage
• Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.1 passage
• Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: 'Online management of rheumatoid arthritis during COVID-19 pandemic' by Zhang1 passage
• Changes in macrophage transcriptome associate with systemic sclerosis and mediate1 passage
• Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial.1 passage
• Changes in the clinical presentation of patients with rheumatoid arthritis from the early 1990s to the years 2010: earlier identification but more severe patient reported outcomes.1 passage
• Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis.1 passage
• Characterisation of the nasal microbiota in granulomatosis with polyangiitis.1 passage
• Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI.1 passage
• Characterising the expression and function of CCL28 and its corresponding receptor, CCR10, in RA pathogenesis.1 passage
• Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.1 passage
• Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.1 passage
• Chemotaxis of Vδ2 T cells to the joints contributes to the pathogenesis of rheumatoid arthritis.1 passage
• Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to '2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine' by Figueroa-Parra1 passage
• Choose wisely: imaging for diagnosis of axial spondyloarthritis.1 passage
• Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases.1 passage
• Chronic NSAID use and long-term decline of renal function in a prospective rheumatoid arthritis cohort study.1 passage
• Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials.1 passage
• Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts.1 passage
• Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus.1 passage
• CircSERPINE2 protects against osteoarthritis by targeting miR-1271 and ETS-related gene.1 passage
• Circular RNA VMA21 protects against intervertebral disc degeneration through targeting miR-200c and X linked inhibitor-of-apoptosis protein.1 passage
• Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis.1 passage
• Circulating blood metabolite trajectories and risk of rheumatoid arthritis among military personnel in the Department of Defense Biorepository.1 passage
• Circulating follicular helper T cells are increased in systemic sclerosis and promote plasmablast differentiation through the IL-21 pathway which can be inhibited by ruxolitinib.1 passage
• Circulating microbial small RNAs are altered in patients with rheumatoid arthritis.1 passage
• Classification criteria for autoinflammatory recurrent fevers.1 passage
• Classification of axial SpA based on positive imaging (radiographs and/or MRI of the sacroiliac joints) by local rheumatologists or radiologists versus central trained readers in the DESIR cohort.1 passage
• Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation.1 passage
• Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.1 passage
• Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.1 passage
• Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).1 passage
• Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.1 passage
• Clinical and radiological outcomes of 5-year drug-free remission-steered treatment in patients with early arthritis: IMPROVED study.1 passage
• Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes.1 passage
• Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial.1 passage
• Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.1 passage
• Clinical characteristics and genetic analyses of 187 patients with undefined autoinflammatory diseases.1 passage
• Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China 'hot spot' versus in US 'hot spot': similarities and differences.1 passage
• Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot'.1 passage
• Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort.1 passage
• Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the1 passage
• Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study.1 passage
• Clinical factors, anticitrullinated peptide antibodies and MRI-detected subclinical inflammation in relation to progression from clinically suspect arthralgia to arthritis.1 passage
• Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China.1 passage
• Clinical manifestations, disease activity and disease burden of radiographic versus non-radiographic axial spondyloarthritis over 5 years of follow-up in the DESIR cohort.1 passage
• Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.1 passage
• Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.1 passage
• Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.1 passage
• Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts.1 passage
• Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.1 passage
• Clinical significance of worsening versus stable preradiographic MRI lesions in a cohort study of persons at higher risk for knee osteoarthritis.1 passage
• Clinical symptoms and associated vascular imaging findings in Takayasu's arteritis compared to giant cell arteritis.1 passage
• Clinical trials in children and adolescents with systemic lupus erythematosus: methodological aspects, regulatory landscape and future opportunities.1 passage
• Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.1 passage
• Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials.1 passage
• Combination of human umbilical cord mesenchymal stem (stromal) cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis.1 passage
• Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.1 passage
• Combined genetic analysis of juvenile idiopathic arthritis clinical subtypes identifies novel risk loci, target genes and key regulatory mechanisms.1 passage
• Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity.1 passage
• Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.1 passage
• Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka1 passage
• Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh1 passage
• Comment on: 'Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand1 passage
• Common language description of the term rheumatic and musculoskeletal diseases (RMDs) for use in communication with the lay public, healthcare providers and other stakeholders endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).1 passage
• Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study.1 passage
• Common mental disorders within chronic inflammatory disorders: a primary care database prospective investigation.1 passage
• Comorbidities in patients with gout prior to and following diagnosis: case-control study.1 passage
• Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero.1 passage
• Comparative effectiveness of allopurinol versus febuxostat for preventing incident renal disease in older adults: an analysis of Medicare claims data.1 passage
• Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.1 passage
• Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.1 passage
• Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial.1 passage
• Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.1 passage
• Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials.1 passage
• Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.1 passage
• Comparing image analysis approaches versus expert readers: the relation of knee radiograph features to knee pain.1 passage
• Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries.1 passage
• Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.1 passage
• Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study.1 passage
• Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.1 passage
• Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study).1 passage
• Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).1 passage
• Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.1 passage
• Comparison of magnetic resonance angiography and1 passage
• Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren's syndrome with other sets of criteria in Japanese patients.1 passage
• Comparison of the effects of tocilizumab monotherapy and adalimumab in combination with methotrexate on bone erosion repair in rheumatoid arthritis.1 passage
• Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.1 passage
• Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.1 passage
• Comparison of two dose escalation strategies of methotrexate in active rheumatoid arthritis: a multicentre, parallel group, randomised controlled trial.1 passage
• Compendium of skin molecular signatures identifies key pathological features associated with fibrosis in systemic sclerosis.1 passage
• Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.1 passage
• Composition of TWIST1 dimers regulates fibroblast activation and tissue fibrosis.1 passage
• Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes.1 passage
• Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?1 passage
• Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.1 passage
• Concordance between inflammation at physical examination and on MRI in patients with early arthritis.1 passage
• Connective tissue growth factor contributes to joint homeostasis and osteoarthritis severity by controlling the matrix sequestration and activation of latent TGFβ.1 passage
• Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD.1 passage
• Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study.1 passage
• Consensus-based recommendations for the management of juvenile dermatomyositis.1 passage
• Consensus-based recommendations for the management of juvenile localised scleroderma.1 passage
• Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative.1 passage
• Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases.1 passage
• Constitutional morphological features and risk of hip osteoarthritis: a case-control study using standard radiographs.1 passage
• Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y).1 passage
• Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndrome.1 passage
• Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic.1 passage
• Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.1 passage
• Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli1 passage
• Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.1 passage
• Correspondence on 'Immunogenicity and safety of anti-SARS-Cov-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.1 passage
• Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries'.1 passage
• Correspondence on 'Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab'.1 passage
• Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'.1 passage
• Correspondence to: 'Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'.1 passage
• Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial.1 passage
• Costs for hospital care, drugs and lost work days in incident and prevalent rheumatoid arthritis: how large, and how are they distributed?1 passage
• Criterion validity of ultrasound in the identification of calcium pyrophosphate crystal deposits at the knee: an OMERACT ultrasound study.1 passage
• Critical role for arginase II in osteoarthritis pathogenesis.1 passage
• Critical role of neutrophil extracellular traps (NETs) in patients with Behcet's disease.1 passage
• Cross-phenotype analysis of Immunochip data identifies1 passage
• Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis.1 passage
• Cross-sectional and longitudinal associations between circulating leptin and knee cartilage thickness in older adults.1 passage
• Crystal structure of Porphyromonas gingivalis peptidylarginine deiminase: implications for autoimmunity in rheumatoid arthritis.1 passage
• Current challenges in the development of new treatments for lupus.1 passage
• Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: a systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica.1 passage
• Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial.1 passage
• Cytosolic 5'-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis.1 passage
• DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study.1 passage
• DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis.1 passage
• DNA methylation mapping identifies gene regulatory effects in patients with systemic lupus erythematosus.1 passage
• Dactylitis is an indicator of a more severe phenotype independently associated with greater SJC, CRP, ultrasound synovitis and erosive damage in DMARD-naive early psoriatic arthritis.1 passage
• Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.1 passage
• Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.1 passage
• Decreased chance of a live born child in women with rheumatoid arthritis after assisted reproduction treatment: a nationwide cohort study.1 passage
• Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with rheumatoid arthritis.1 passage
• Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis.1 passage
• Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.1 passage
• Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven et al.1 passage
• Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force.1 passage
• Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).1 passage
• Defining refractory rheumatoid arthritis.1 passage
• Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology.1 passage
• Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).1 passage
• Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.1 passage
• Deregulation of microRNA expression in purified T and B lymphocytes from patients with primary Sjögren's syndrome.1 passage
• Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.1 passage
• Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays.1 passage
• Determinants of happiness and quality of life in patients with rheumatoid arthritis: a structural equation modelling approach.1 passage
• Determinants of psychological well-being in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data.1 passage
• Determining factors related to poor quality of life in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS).1 passage
• Determining in which pre-arthritis stage HLA-shared epitope alleles and smoking exert their effect on the development of rheumatoid arthritis.1 passage
• Development and initial validation of international severity scoring system for familial Mediterranean fever (ISSF).1 passage
• Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis.1 passage
• Development and psychometric validation of a patient-reported outcome measure to assess fears in rheumatoid arthritis and axial spondyloarthritis: the Fear Assessment in Inflammatory Rheumatic diseases (FAIR) questionnaire.1 passage
• Development and validation of a methotrexate adherence assay.1 passage
• Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.1 passage
• Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (ScleroID) questionnaire.1 passage
• Development and validation of prediction models to estimate risk of primary total hip and knee replacements using data from the UK: two prospective open cohorts using the UK Clinical Practice Research Datalink.1 passage
• Development and validation of risk stratification trees for incident slow gait speed in persons at high risk for knee osteoarthritis.1 passage
• Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.1 passage
• Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis.1 passage
• Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology.1 passage
• Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis.1 passage
• Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research.1 passage
• Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS.1 passage
• Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20).1 passage
• Development of a prediction model for inpatient gout flares in people with comorbid gout.1 passage
• Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis.1 passage
• Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project.1 passage
• Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort.1 passage
• Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies.1 passage
• Development of the autoinflammatory disease damage index (ADDI).1 passage
• Diagnosis of osteoporosis in statin-treated patients is dose-dependent.1 passage
• Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: 'Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia' by Guilpain1 passage
• Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS).1 passage
• Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: results from the Danish nationwide DANBIO registry.1 passage
• Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis.1 passage
• Dietary intake of fibre and risk of knee osteoarthritis in two US prospective cohorts.1 passage
• Differences and similarities in rheumatology specialty training programmes across European countries.1 passage
• Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis.1 passage
• Differences in the symptomatic phase preceding ACPA-positive and ACPA-negative RA: a longitudinal study in arthralgia during progression to clinical arthritis.1 passage
• Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification.1 passage
• Differential DNA methylation and expression of inflammatory and zinc transporter genes defines subgroups of osteoarthritic hip patients.1 passage
• Differential ubiquitination in NETs regulates macrophage responses in systemic lupus erythematosus.1 passage
• Digital crowdsourcing: unleashing its power in rheumatology.1 passage
• Digital ulcers predict a worse disease course in patients with systemic sclerosis.1 passage
• Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis.1 passage
• Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study.1 passage
• Disability and not osteoarthritis predicts cardiovascular disease: a prospective population-based cohort study.1 passage
• Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study.1 passage
• Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry.1 passage
• Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.1 passage
• Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis.1 passage
• Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: data from the Osteoarthritis Initiative.1 passage
• Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.1 passage
• Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.1 passage
• Disease activity is associated with reduced left ventricular systolic myocardial function in patients with rheumatoid arthritis.1 passage
• Disease activity is longitudinally related to sacroiliac inflammation on MRI in male patients with axial spondyloarthritis: 2-years of the DESIR cohort.1 passage
• Disease activity states of the DAPSA, a psoriatic arthritis specific instrument, are valid against functional status and structural progression.1 passage
• Disease activity trajectories in early axial spondyloarthritis: results from the DESIR cohort.1 passage
• Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis.1 passage
• Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.1 passage
• Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.1 passage
• Disease progression into adulthood and predictors of long-term active disease in juvenile idiopathic arthritis.1 passage
• Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.1 passage
• Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms.1 passage
• Disease-modifying effect of strontium ranelate in a subset of patients from the Phase III knee osteoarthritis study SEKOIA using quantitative MRI: reduction in bone marrow lesions protects against cartilage loss.1 passage
• Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging.1 passage
• Do RA or TNF inhibitors increase the risk of cervical neoplasia or of recurrence of previous neoplasia? A nationwide study from Sweden.1 passage
• Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study.1 passage
• Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts.1 passage
• Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?1 passage
• Does a family history of RA influence the clinical presentation and treatment response in RA?1 passage
• Does biologic therapy impact the development of PsA among patients with psoriasis?1 passage
• Does cartilage loss cause pain in osteoarthritis and if so, how much?1 passage
• Does flare trial design affect the effect size of non-steroidal anti-inflammatory drugs in symptomatic osteoarthritis? A systematic review and meta-analysis.1 passage
• Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.1 passage
• Does knee replacement surgery for osteoarthritis improve survival? The jury is still out.1 passage
• Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis?1 passage
• Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?1 passage
• Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis.1 passage
• Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study.1 passage
• Downregulation of miR-193b in systemic sclerosis regulates the proliferative vasculopathy by urokinase-type plasminogen activator expression.1 passage
• Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.1 passage
• Drug-free sustained remission or spontaneous remission by natural history in rheumatoid arthritis? An unsolved question: comment on the article of Ajeganova1 passage
• Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database.1 passage
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.1 passage
• Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.1 passage
• Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study.1 passage
• Dynamical trajectory of glucocorticoids tapering and discontinuation in patients with rheumatoid arthritis commencing glucocorticoids with csDMARDs: a real-world data from 2009 to 2020.1 passage
• Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in patients with ankylosing spondylitis.1 passage
• Dysbiosis in the oral microbiomes of anti-CCP positive individuals at risk of developing rheumatoid arthritis.1 passage
• Dysregulated bioenergetics: a key regulator of joint inflammation.1 passage
• Dysregulated neutrophil responses and neutrophil extracellular trap formation and degradation in PAPA syndrome.1 passage
• ERAP2 functional knockout in humans does not alter surface heavy chains or HLA-B27, inflammatory cytokines or endoplasmic reticulum stress markers.1 passage
• EULAR Points to Consider (PtC) for designing, analysing and reporting of studies with work participation as an outcome domain in patients with inflammatory arthritis.1 passage
• EULAR Points to Consider for the use of imaging to guide interventional procedures in patients with rheumatic and musculoskeletal diseases (RMDs).1 passage
• EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis.1 passage
• EULAR definition of difficult-to-treat rheumatoid arthritis.1 passage
• EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.1 passage
• EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.1 passage
• EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.1 passage
• EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases.1 passage
• EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.1 passage
• EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2.1 passage
• EULAR recommendations for a core data set for pregnancy registries in rheumatology.1 passage
• EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.1 passage
• EULAR recommendations for intra-articular therapies.1 passage
• EULAR recommendations for patient education for people with inflammatory arthritis.1 passage
• EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.1 passage
• EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies.1 passage
• EULAR recommendations for the management of antiphospholipid syndrome in adults.1 passage
• EULAR recommendations for the management of familial Mediterranean fever.1 passage
• EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.1 passage
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.1 passage
• EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.1 passage
• EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs).1 passage
• EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice.1 passage
• EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis.1 passage
• EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.1 passage
• EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome.1 passage
• EULAR revised recommendations for the management of fibromyalgia.1 passage
• EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice.1 passage
• EULAR/EFORT recommendations for management of patients older than 50 years with a fragility fracture and prevention of subsequent fractures.1 passage
• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.1 passage
• EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases.1 passage
• EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries.1 passage
• Early T2 changes predict onset of radiographic knee osteoarthritis: data from the osteoarthritis initiative.1 passage
• Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).1 passage
• Early predictors of prognosis in juvenile idiopathic arthritis: a systematic literature review.1 passage
• Economic burden of rheumatoid arthritis: a systematic review of literature in biologic era.1 passage
• Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists.1 passage
• Ectopic RASGRP2 (CalDAG-GEFI) expression in rheumatoid synovium contributes to the development of destructive arthritis.1 passage
• Ectopic expression of CXCL13, BAFF, APRIL and LT-β is associated with artery tertiary lymphoid organs in giant cell arteritis.1 passage
• Effect of a treat-to-target intervention of cardiovascular risk factors on subclinical and clinical atherosclerosis in rheumatoid arthritis: a randomised clinical trial.1 passage
• Effect of bisphosphonates on knee replacement surgery.1 passage
• Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).1 passage
• Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.1 passage
• Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis.1 passage
• Effect of home-based hand exercises in women with hand osteoarthritis: a randomised controlled trial.1 passage
• Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.1 passage
• Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.1 passage
• Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.1 passage
• Effect of pregnancy on disease flares in patients with systemic lupus erythematosus.1 passage
• Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy.1 passage
• Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis.1 passage
• Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study.1 passage
• Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.1 passage
• Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series.1 passage
• Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.1 passage
• Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results.1 passage
• Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.1 passage
• Effectiveness of low-dose radiation therapy on symptoms in patients with knee osteoarthritis: a randomised, double-blinded, sham-controlled trial.1 passage
• Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.1 passage
• Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.1 passage
• Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study.1 passage
• Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.1 passage
• Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study.1 passage
• Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study.1 passage
• Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.1 passage
• Effects of bariatric surgery on gout incidence in the Swedish Obese Subjects study: a non-randomised, prospective, controlled intervention trial.1 passage
• Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims.1 passage
• Effects of face masks on oxygen saturation and functional measures in patients with connective tissue disorder-associated interstitial lung disease.1 passage
• Effects of maternal medication on long-term outcome in congenital heart block remain to be established. Response to: 'Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero' by Satis1 passage
• Effects of needs-based patient education on self-efficacy and health outcomes in people with rheumatoid arthritis: a multicentre, single blind, randomised controlled trial.1 passage
• Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.1 passage
• Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.1 passage
• Efficacy and safety of NI-0101, an anti-toll-like receptor 4 monoclonal antibody, in patients with rheumatoid arthritis after inadequate response to methotrexate: a phase II study.1 passage
• Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease.1 passage
• Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.1 passage
• Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.1 passage
• Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis.1 passage
• Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.1 passage
• Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial.1 passage
• Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).1 passage
• Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.1 passage
• Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study.1 passage
• Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study.1 passage
• Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.1 passage
• Efficacy and safety of fasinumab in patients with chronic low back pain: a phase II/III randomised clinical trial.1 passage
• Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).1 passage
• Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).1 passage
• Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.1 passage
• Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study.1 passage
• Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).1 passage
• Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.1 passage
• Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.1 passage
• Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.1 passage
• Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.1 passage
• Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.1 passage
• Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).1 passage
• Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.1 passage
• Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study.1 passage
• Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain.1 passage
• Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.1 passage
• Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.1 passage
• Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study.1 passage
• Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.1 passage
• Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).1 passage
• Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.1 passage
• Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.1 passage
• Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial.1 passage
• Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).1 passage
• Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.1 passage
• Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings.1 passage
• Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial.1 passage
• Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.1 passage
• Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study.1 passage
• Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.1 passage
• Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.1 passage
• Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study.1 passage
• Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial.1 passage
• Elevated EPSTI1 promote B cell hyperactivation through NF-κB signalling in patients with primary Sjögren's syndrome.1 passage
• Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis.1 passage
• Elevated circulating levels of interferon-γ and interferon-γ-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.1 passage
• Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry.1 passage
• Emergent high fatality lung disease in systemic juvenile arthritis.1 passage
• Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis in the Nurses' Health Study II.1 passage
• Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome.1 passage
• Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis.1 passage
• Endothelin-1 promotes vascular smooth muscle cell migration across the artery wall: a mechanism contributing to vascular remodelling and intimal hyperplasia in giant-cell arteritis.1 passage
• Enriching case selection for imminent RA: the use of anti-CCP antibodies in individuals with new non-specific musculoskeletal symptoms - a cohort study.1 passage
• Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.1 passage
• Enthesitis in patients with psoriatic arthritis, axial spondyloarthritis and healthy subjects assessed by 'head-to-toe' whole-body MRI and clinical examination.1 passage
• Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins.1 passage
• Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors.1 passage
• Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece.1 passage
• Epidemiology and socioeconomic impact of the rheumatic diseases on indigenous people: an invisible syndemic public health problem.1 passage
• Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis.1 passage
• Erosive osteoarthritis: a more severe form of radiographic hand osteoarthritis rather than a distinct entity?1 passage
• Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH/OARSI OA Biomarkers Consortium.1 passage
• Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis.1 passage
• Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial.1 passage
• European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.1 passage
• European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance.1 passage
• European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view.1 passage
• European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative.1 passage
• European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative.1 passage
• European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative.1 passage
• Evaluating diagnostic criteria for macrophage activation syndrome in patients with adult onset Still's disease. Response to: 'Comparison of MS score and HScore for the diagnosis of adult-onset Still's disease associated macrophage activation syndrome' by Zhang1 passage
• Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.1 passage
• Evaluating processes underlying the predictive value of baseline erosions for future radiological damage in early rheumatoid arthritis.1 passage
• Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.1 passage
• Evaluation of the change in structural radiographic sacroiliac joint damage after 2 years of etanercept therapy (EMBARK trial) in comparison to a contemporary control cohort (DESIR cohort) in recent onset axial spondyloarthritis.1 passage
• Evaluation of the effect of baseline MRI sacroiliitis and C reactive protein status on etanercept treatment response in non-radiographic axial spondyloarthritis: a post hoc analysis of the EMBARK study.1 passage
• Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study.1 passage
• Evaluation of the validity of the different arms of the ASAS set of criteria for axial spondyloarthritis and description of the different imaging abnormalities suggestive of spondyloarthritis: data from the DESIR cohort.1 passage
• Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre.1 passage
• Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update.1 passage
• Evidence that tissue resident human enthesis γδT-cells can produce IL-17A independently of IL-23R transcript expression.1 passage
• Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers.1 passage
• Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever.1 passage
• Evolution of cost structures in rheumatoid arthritis over the past decade.1 passage
• Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study.1 passage
• Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus.1 passage
• Examination of overall treatment effect and the proportion attributable to contextual effect in osteoarthritis: meta-analysis of randomised controlled trials.1 passage
• Exercise and education versus saline injections for knee osteoarthritis: a randomised controlled equivalence trial.1 passage
• Exercise therapy may postpone total hip replacement surgery in patients with hip osteoarthritis: a long-term follow-up of a randomised trial.1 passage
• Exome-wide association study identifies four novel loci for systemic lupus erythematosus in Han Chinese population.1 passage
• Expansion of T follicular helper-T helper 1 like cells through epigenetic regulation by signal transducer and activator of transcription factors.1 passage
• Exposure to passive smoking and rheumatoid arthritis risk: results from the Swedish EIRA study.1 passage
• Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis.1 passage
• Expression of chemokines CXCL4 and CXCL7 by synovial macrophages defines an early stage of rheumatoid arthritis.1 passage
• Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis.1 passage
• FGF2 induces RANKL gene expression as well as IL1β regulated MHC class II in human bone marrow-derived mesenchymal progenitor stromal cells.1 passage
• FGFR3 deficiency enhances CXCL12-dependent chemotaxis of macrophages via upregulating CXCR7 and aggravates joint destruction in mice.1 passage
• FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis.1 passage
• FUT2: filling the gap between genes and environment in Behçet's disease?1 passage
• Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.1 passage
• Factors associated with change in radiographic damage scores in gout: a prospective observational study.1 passage
• Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.1 passage
• Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort.1 passage
• Factors associated with long-term cardiac dysfunction in neonatal lupus.1 passage
• Factors associated with progression to inflammatory arthritis in first-degree relatives of individuals with RA following autoantibody positive screening in a non-clinical setting.1 passage
• Faecal microbiota study reveals specific dysbiosis in spondyloarthritis.1 passage
• Faecal microbiota transplantation from metabolically compromised human donors accelerates osteoarthritis in mice.1 passage
• Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies.1 passage
• Familial aggregation of arthritis-related diseases in seropositive and seronegative rheumatoid arthritis: a register-based case-control study in Sweden.1 passage
• Familial aggregation of gout and relative genetic and environmental contributions: a nationwide population study in Taiwan.1 passage
• Familial chilblain lupus due to a gain-of-function mutation in STING.1 passage
• Fast diagnostic test for familial Mediterranean fever based on a kinase inhibitor.1 passage
• Fatigue in SLE: diagnostic and pathogenic impact of anti-N-methyl-D-aspartate receptor (NMDAR) autoantibodies.1 passage
• Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment.1 passage
• Fertility in women with rheumatoid arthritis: influence of disease activity and medication.1 passage
• Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).1 passage
• Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).1 passage
• Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.1 passage
• Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.1 passage
• Fine-mapping the MHC locus in juvenile idiopathic arthritis (JIA) reveals genetic heterogeneity corresponding to distinct adult inflammatory arthritic diseases.1 passage
• First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL,1 passage
• First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis.1 passage
• First external validation of sensitivity and specificity of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort.1 passage
• First step in the development of an ultrasound joint inflammation score for rheumatoid arthritis using a data-driven approach.1 passage
• First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort.1 passage
• Fish oil in knee osteoarthritis: a randomised clinical trial of low dose versus high dose.1 passage
• Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.1 passage
• Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.1 passage
• Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.1 passage
• Four-month metacarpal bone mineral density loss predicts radiological joint damage progression after 1 year in patients with early rheumatoid arthritis: exploratory analyses from the IMPROVED study.1 passage
• Free fatty acids: potential proinflammatory mediators in rheumatic diseases.1 passage
• Frequency of MRI changes suggestive of axial spondyloarthritis in the axial skeleton in a large population-based cohort of individuals aged <45 years.1 passage
• Frequency of tumour necrosis factor alpha receptor superfamily 1A multiple sclerosis-associated variants in patients with rheumatoid arthritis with anti-tumour necrosis factor therapy-related demyelinating complications.1 passage
• Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases.1 passage
• From Modic 1 vertebral-endplate subchondral bone signal changes detected by MRI to the concept of 'active discopathy'.1 passage
• From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift?1 passage
• Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.1 passage
• Functional genomics of autoimmune diseases.1 passage
• GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.1 passage
• GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes.1 passage
• Galectin-9 is an easy to measure biomarker for the interferon signature in systemic lupus erythematosus and antiphospholipid syndrome.1 passage
• Galectin-9 reflects the interferon signature and correlates with disease activity in systemic autoimmune diseases. Response to: 'Biomarkers: to be or not to be' by Yavuz and Rönnblom.1 passage
• Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice.1 passage
• Gene copy-number variations (CNVs) of complement C4 and C4A deficiency in genetic risk and pathogenesis of juvenile dermatomyositis.1 passage
• Gene editing for inflammatory disorders.1 passage
• Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus.1 passage
• Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications.1 passage
• Genetic association of ankylosing spondylitis with TBX21 influences T-bet and pro-inflammatory cytokine expression in humans and SKG mice as a model of spondyloarthritis.1 passage
• Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis.1 passage
• Genetic variants in ANCA-associated vasculitis: a meta-analysis.1 passage
• Genetic variants shape rheumatoid arthritis-specific transcriptomic features in CD41 passage
• Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis.1 passage
• Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus.1 passage
• Genetics of rheumatoid arthritis: 2018 status.1 passage
• Genome-wide DNA methylation analysis in dermal fibroblasts from patients with diffuse and limited systemic sclerosis reveals common and subset-specific DNA methylation aberrancies.1 passage
• Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes.1 passage
• Genome-wide association and functional studies identify a role for IGFBP3 in hip osteoarthritis.1 passage
• Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand.1 passage
• Genome-wide association study identifies1 passage
• Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis.1 passage
• Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.1 passage
• Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout.1 passage
• Genome-wide meta-analysis reveals shared new1 passage
• Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.1 passage
• Genome-wide whole blood transcriptome profiling in a large European cohort of systemic sclerosis patients.1 passage
• Genomic Risk Score impact on susceptibility to systemic sclerosis.1 passage
• Genomic risk scores for juvenile idiopathic arthritis and its subtypes.1 passage
• Genomic sequencing and functional analyses identify MAP4K3/GLK germline and somatic variants associated with systemic lupus erythematosus.1 passage
• Geospatial clustering of childhood IgA vasculitis and IgA vasculitis-associated nephritis.1 passage
• Germinal centres in diagnostic labial gland biopsies of patients with primary Sjögren's syndrome are not predictive for parotid MALT lymphoma development.1 passage
• Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity.1 passage
• Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma.1 passage
• Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.1 passage
• Global ultrasound assessment of structural lesions in osteoarthritis: a reliability study by the OMERACT ultrasonography group on scoring cartilage and osteophytes in finger joints.1 passage
• Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017.1 passage
• Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017.1 passage
• Glucocorticoid discontinuation in patients with early rheumatoid and undifferentiated arthritis: a post-hoc analysis of the BeSt and IMPROVED studies.1 passage
• Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens.1 passage
• Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.1 passage
• Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study.1 passage
• Gout and pseudo-gout-related crystals promote GLUT1-mediated glycolysis that governs NLRP3 and interleukin-1β activation on macrophages.1 passage
• Gout and the risk of Alzheimer's disease: a population-based, BMI-matched cohort study.1 passage
• Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.1 passage
• Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study.1 passage
• H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production.1 passage
• HLA class I and II alleles in susceptibility to ankylosing spondylitis.1 passage
• HLA-A 31:01 is not associated with the development of methotrexate pneumonitis in the UK population: results from a genome-wide association study.1 passage
• HLA-B27 alters BMP/TGFβ signalling in1 passage
• Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.1 passage
• Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease: data from the Framingham heart study.1 passage
• Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.1 passage
• Health status has improved more in women than in men with rheumatoid arthritis from 1994 to 2009: results from the Oslo rheumatoid arthritis register.1 passage
• Health-related quality of life in patients with psoriatic and rheumatoid arthritis: data from the prospective multicentre NOR-DMARD study compared with Norwegian general population controls.1 passage
• Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis.1 passage
• High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort.1 passage
• High erythrocyte levels of the n-6 polyunsaturated fatty acid linoleic acid are associated with lower risk of subsequent rheumatoid arthritis in a southern European nested case-control study.1 passage
• High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort.1 passage
• High frequency of variants in genes associated with primary immunodeficiencies in patients with rheumatic diseases with secondary hypogammaglobulinaemia.1 passage
• High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus.1 passage
• High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission.1 passage
• High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block.1 passage
• High prevalence of spondyloarthritis-like MRI lesions in postpartum women: a prospective analysis in relation to maternal, child and birth characteristics.1 passage
• High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci.1 passage
• High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis.1 passage
• High-sensitive troponin is associated with subclinical imaging biosignature of inflammatory cardiovascular involvement in systemic lupus erythematosus.1 passage
• Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast-like synoviocytes.1 passage
• Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.1 passage
• Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study.1 passage
• Horizontal fissuring at the osteochondral interface: a novel and unique pathological feature in patients with obesity-related osteoarthritis.1 passage
• Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study.1 passage
• Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries.1 passage
• How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.1 passage
• How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries.1 passage
• How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?1 passage
• How to treat patients with rheumatoid arthritis when methotrexate has failed? The use of a multiple propensity score to adjust for confounding by indication in observational studies.1 passage
• How well do ACPA discriminate and predict RA in the general population: a study based on 12 590 population-representative Swedish twins.1 passage
• Human SLE variant1 passage
• Humanised effector-null FcγRIIA antibody inhibits immune complex-mediated proinflammatory responses.1 passage
• Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.1 passage
• Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA).1 passage
• Huntingtin-interacting protein 1 (HIP1) regulates arthritis severity and synovial fibroblast invasiveness by altering PDGFR and Rac1 signalling.1 passage
• Hydroxychloroquine dosing in systemic lupus erythematosus: response to 'Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis1 passage
• Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase.1 passage
• Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation.1 passage
• Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.1 passage
• Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate.1 passage
• Hypomethylation of1 passage
• Hypoxia and STAT3 signalling interactions regulate pro-inflammatory pathways in rheumatoid arthritis.1 passage
• IFI44L promoter methylation as a blood biomarker for systemic lupus erythematosus.1 passage
• IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study.1 passage
• IL-22 capacitates dermal fibroblast responses to TNF in scleroderma.1 passage
• IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors.1 passage
• IL-38 overexpression induces anti-inflammatory effects in mice arthritis models and in human macrophages in vitro.1 passage
• IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis.1 passage
• IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis.1 passage
• Ideal target for psoriatic arthritis? Comparison of remission and low disease activity states in a real-life cohort.1 passage
• Identification and characterisation of citrullinated antigen-specific B cells in peripheral blood of patients with rheumatoid arthritis.1 passage
• Identification of1 passage
• Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism.1 passage
• Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss.1 passage
• Identification of a novel locus on chromosome 2q13, which predisposes to clinical vertebral fractures independently of bone density.1 passage
• Identification of a transitional fibroblast function in very early rheumatoid arthritis.1 passage
• Identification of an immunodominant peptide from citrullinated tenascin-C as a major target for autoantibodies in rheumatoid arthritis.1 passage
• Identification of anticitrullinated protein antibody reactivities in a subset of anti-CCP-negative rheumatoid arthritis: association with cigarette smoking and HLA-DRB1 'shared epitope' alleles.1 passage
• Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints-an international multiobserver study by the OMERACT Calcium Pyrophosphate Deposition Disease Ultrasound Subtask Force.1 passage
• Identification of myeloid cells in the human enthesis as the main source of local IL-23 production.1 passage
• Identification of new susceptibility loci associated with rheumatoid arthritis.1 passage
• Identification of novel antiacetylated vimentin antibodies in patients with early inflammatory arthritis.1 passage
• Identification of patients with gout: elaboration of a questionnaire for epidemiological studies.1 passage
• Identification of rare coding variants in1 passage
• Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene.1 passage
• IgM rheumatoid factor amplifies the inflammatory response of macrophages induced by the rheumatoid arthritis-specific immune complexes containing anticitrullinated protein antibodies.1 passage
• Imaging modalities for the classification of gout: systematic literature review and meta-analysis.1 passage
• Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation.1 passage
• Immune response profiling of patients with spondyloarthritis reveals signalling networks mediating TNF-blocker function in vivo.1 passage
• Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.1 passage
• Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.1 passage
• Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.1 passage
• Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up.1 passage
• Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.1 passage
• Immunome perturbation is present in patients with juvenile idiopathic arthritis who are in remission and will relapse upon anti-TNFα withdrawal.1 passage
• Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.1 passage
• Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery.1 passage
• Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.1 passage
• Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.1 passage
• Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).1 passage
• Impact of allopurinol on risk of myocardial infarction.1 passage
• Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial.1 passage
• Impact of biological therapy on work outcomes in patients with axial spondyloarthritis: results from the British Society for Rheumatology Biologics Register (BSRBR-AS) and meta-analysis.1 passage
• Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.1 passage
• Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.1 passage
• Impact of rheumatoid arthritis on major cardiovascular events in patients with and without coronary artery disease.1 passage
• Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.1 passage
• Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.1 passage
• Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study.1 passage
• Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort.1 passage
• Impact of the leucocyte immunoglobulin-like receptor A3 (LILRA3) on susceptibility and subphenotypes of systemic lupus erythematosus and Sjögren's syndrome.1 passage
• Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus.1 passage
• Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis.1 passage
• Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility).1 passage
• Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.1 passage
• Implementation of the EULAR cardiovascular risk management guideline in patients with rheumatoid arthritis: results of a successful collaboration between primary and secondary care.1 passage
• Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab.1 passage
• Implication of the deacetylase sirtuin-1 on synovial angiogenesis and persistence of experimental arthritis.1 passage
• Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.1 passage
• Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study.1 passage
• Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history.1 passage
• Improved survival in rheumatoid arthritis: a general population-based cohort study.1 passage
• Improved survival with renal transplantation for end-stage renal disease due to granulomatosis with polyangiitis: data from the United States Renal Data System.1 passage
• Improvement in 5-year mortality in incident rheumatoid arthritis compared with the general population-closing the mortality gap.1 passage
• Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study.1 passage
• Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework.1 passage
• In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment.1 passage
• In primary Sjögren's syndrome high absolute numbers and proportions of B cells in parotid glands predict responsiveness to rituximab as defined by ESSDAI, but not by SSRI.1 passage
• In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?1 passage
• In silico validation of the Autoinflammatory Disease Damage Index.1 passage
• In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness?1 passage
• In vitro elimination of autoreactive B cells from rheumatoid arthritis patients by universal chimeric antigen receptor T cells.1 passage
• In wealthier countries, patients perceive worse impact of the disease although they have lower objectively assessed disease activity: results from the cross-sectional COMORA study.1 passage
• Inadequate response to treat-to-target methotrexate therapy in patients with new-onset rheumatoid arthritis: development and validation of clinical predictors.1 passage
• Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden.1 passage
• Incidence and predictors for cardiovascular events in patients with psoriatic arthritis.1 passage
• Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.1 passage
• Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study.1 passage
• Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials.1 passage
• Incidence and time trends of joint surgery in patients with psoriatic arthritis: a register-based time series and cohort study from Denmark.1 passage
• Incidence of autoimmune diseases in a nationwide HIV/AIDS patient cohort in Taiwan, 2000-2012.1 passage
• Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan.1 passage
• Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs: an interrupted time-series analysis using nationwide Danish healthcare registers.1 passage
• Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.1 passage
• Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials.1 passage
• Incidence trend of five common musculoskeletal disorders from 1990 to 2017 at the global, regional and national level: results from the global burden of disease study 2017.1 passage
• Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study.1 passage
• Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.1 passage
• Increased IgG4 responses to multiple food and animal antigens indicate a polyclonal expansion and differentiation of pre-existing B cells in IgG4-related disease.1 passage
• Increased arterial wall inflammation in patients with ankylosing spondylitis is reduced by statin therapy.1 passage
• Increased autophagy is cytoprotective against podocyte injury induced by antibody and interferon-α in lupus nephritis.1 passage
• Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis.1 passage
• Increased function of pronociceptive TRPV1 at the level of the joint in a rat model of osteoarthritis pain.1 passage
• Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.1 passage
• Increased prevalence and severity of radiographic hand osteoarthritis in patients with HIV-1 infection associated with metabolic syndrome: data from the cross-sectional METAFIB-OA study.1 passage
• Increased prevalence of coronary plaque in patients with psoriatic arthritis without prior diagnosis of coronary artery disease.1 passage
• Increased risk of osteoporotic fractures in patients with systemic sclerosis: a nationwide population-based study.1 passage
• Increased risk of rheumatoid arthritis among mothers with children who carry1 passage
• Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink.1 passage
• Increasing synovitis and bone marrow lesions are associated with incident joint tenderness in hand osteoarthritis.1 passage
• Independent impact of gout on the risk of diabetes mellitus among women and men: a population-based, BMI-matched cohort study.1 passage
• Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).1 passage
• Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.1 passage
• Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.1 passage
• Infections and respiratory tract disease as risk factors for idiopathic inflammatory myopathies: a population-based case1 passage
• Infections and the risk of incident giant cell arteritis: a population-based, case-control study.1 passage
• Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.1 passage
• Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020.1 passage
• Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.1 passage
• Inflammatory back pain criteria perform well in subset of patients with active axial psoriatic arthritis but not among patients with established axial disease.1 passage
• Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression.1 passage
• Inflammatory cytokines shape a changing DNA methylome in monocytes mirroring disease activity in rheumatoid arthritis.1 passage
• Inflammatory ultrasound features show independent associations with progression of structural damage after over 2 years of follow-up in patients with hand osteoarthritis.1 passage
• Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries.1 passage
• Influence of TYK2 in systemic sclerosis susceptibility: a new locus in the IL-12 pathway.1 passage
• Influence of changes in cholesterol levels and disease activity on the 10 years cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients.1 passage
• Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study.1 passage
• Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.1 passage
• Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19?1 passage
• Infusion reactions during infliximab treatment are not associated with IgE anti-infliximab antibodies.1 passage
• Inhibition of BATF/JUN transcriptional activity protects against osteoarthritic cartilage destruction.1 passage
• Inhibition of Rac1 activity by controlled release of NSC23766 from chitosan microspheres effectively ameliorates osteoarthritis development in vivo.1 passage
• Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis.1 passage
• Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.1 passage
• Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis.1 passage
• Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial.1 passage
• Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-Act-Early and CAMERA-II treat-to-target trials.1 passage
• Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.1 passage
• Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.1 passage
• Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.1 passage
• Integrin and transcriptomic profiles identify a distinctive synovial CD8+ T cell subpopulation in spondyloarthritis.1 passage
• Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.1 passage
• Interaction between innate immunity and Ro52-induced antibody causes Sjögren's syndrome-like disorder in mice.1 passage
• Interaction between the1 passage
• Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.1 passage
• Interleukin 1 receptor antagonist (1 passage
• Interleukin 12 and interleukin 23 play key pathogenic roles in inflammatory and proliferative pathways in giant cell arteritis.1 passage
• Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.1 passage
• Interleukin-6 and chondrocyte mineralisation act in tandem to promote experimental osteoarthritis.1 passage
• Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis.1 passage
• Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.1 passage
• International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.1 passage
• Intra-articular sprifermin reduces cartilage loss in addition to increasing cartilage gain independent of location in the femorotibial joint: post-hoc analysis of a randomised, placebo-controlled phase II clinical trial.1 passage
• Intramuscular glucocorticoid injection versus placebo injection in hip osteoarthritis: a 12-week blinded randomised controlled trial.1 passage
• Intramuscular versus ultrasound-guided intratenosynovial glucocorticoid injection for tenosynovitis in patients with rheumatoid arthritis: a randomised, double-blind, controlled study.1 passage
• Intrarenal activation of adaptive immune effectors is associated with tubular damage and impaired renal function in lupus nephritis.1 passage
• Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial.1 passage
• Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.1 passage
• Investigation of genetically regulated gene expression and response to treatment in rheumatoid arthritis highlights an association between1 passage
• Is ankylosing spondylitis a risk factor for cardiovascular disease, and how do these risks compare with those in rheumatoid arthritis?1 passage
• Is it time to revisit the role of ultrasound in rheumatoid arthritis management?1 passage
• Is the epidemiology of rheumatoid arthritis changing? Results from a population-based incidence study, 1985-2014.1 passage
• Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM).1 passage
• Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.1 passage
• JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.1 passage
• JAK1-dependent transphosphorylation of JAK2 limits the antifibrotic effects of selective JAK2 inhibitors on long-term treatment.1 passage
• JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis.1 passage
• Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study.1 passage
• Joint inflammation tends to recur in the same joints during the rheumatoid arthritis disease course.1 passage
• Juvenile onset arthritis and pregnancy outcome: a population-based cohort study.1 passage
• Kdm6b regulates cartilage development and homeostasis through anabolic metabolism.1 passage
• Key findings towards optimising adalimumab treatment: the concentration-effect curve.1 passage
• Knee and hip intra-articular adipose tissues (IAATs) compared with autologous subcutaneous adipose tissue: a specific phenotype for a central player in osteoarthritis.1 passage
• Knee extensor strength and body weight in adolescent men and the risk of knee osteoarthritis by middle age.1 passage
• Knee osteoarthritis risk in non-industrial societies undergoing an energy balance transition: evidence from the indigenous Tarahumara of Mexico.1 passage
• Laboratory investigation results influence Physician's Global Assessment (PGA) of disease activity in SLE.1 passage
• Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis.1 passage
• Lack of gene-diuretic interactions on the risk of incident gout: the Nurses' Health Study and Health Professionals Follow-up Study.1 passage
• Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.1 passage
• Large joint involvement at first presentation with RA, an unfavourable feature: results of a large longitudinal study with functioning and DMARD-free sustained remission as outcomes.1 passage
• Large-scale meta-analysis across East Asian and European populations updated genetic architecture and variant-driven biology of rheumatoid arthritis, identifying 11 novel susceptibility loci.1 passage
• Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.1 passage
• Leri's pleonosteosis, a congenital rheumatic disease, results from microduplication at 8q22.1 encompassing GDF6 and SDC2 and provides insight into systemic sclerosis pathogenesis.1 passage
• Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).1 passage
• Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol.1 passage
• Lesional CD4+ IFN-γ+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis.1 passage
• Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?1 passage
• Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in1 passage
• Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.1 passage
• Linking chondrocyte and synovial transcriptional profile to clinical phenotype in osteoarthritis.1 passage
• Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.1 passage
• Loci associated with N-glycosylation of human IgG are not associated with rheumatoid arthritis: a Mendelian randomisation study.1 passage
• Long non-coding RNA HOTAIR drives EZH2-dependent myofibroblast activation in systemic sclerosis through miRNA 34a-dependent activation of NOTCH.1 passage
• Long-term dietary quality and risk of developing rheumatoid arthritis in women.1 passage
• Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study.1 passage
• Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study.1 passage
• Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial.1 passage
• Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.1 passage
• Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis.1 passage
• Long-term outcome in juvenile-onset mixed connective tissue disease: a nationwide Norwegian study.1 passage
• Long-term outcome is better when a methotrexate-based treatment strategy is combined with 10 mg prednisone daily: follow-up after the second Computer-Assisted Management in Early Rheumatoid Arthritis trial.1 passage
• Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis.1 passage
• Long-term outcomes after disease activity-guided dose reduction of TNF inhibition in rheumatoid arthritis: 3-year data of the DRESS study - a randomised controlled pragmatic non-inferiority strategy trial.1 passage
• Long-term outcomes and secondary prevention after acute coronary events in patients with rheumatoid arthritis.1 passage
• Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).1 passage
• Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.1 passage
• Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.1 passage
• Longitudinal validation of periarticular bone area and 3D shape as biomarkers for knee OA progression? Data from the FNIH OA Biomarkers Consortium.1 passage
• Longitudinal versus cross-sectional IL-6 measurements in tocilizumab-treated GCA. Response to: 'Analysis of IL-6 measurement in GCA patients treated with tocilizumab should consider concomitant treatment with prednisone' by Samson and Bonnotte.1 passage
• Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis.1 passage
• Loss of phosphatase and tensin homolog (PTEN) in myeloid cells controls inflammatory bone destruction by regulating the osteoclastogenic potential of myeloid cells.1 passage
• Low RUNX3 expression alters dendritic cell function in patients with systemic sclerosis and contributes to enhanced fibrosis.1 passage
• Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.1 passage
• Low immunogenicity of tocilizumab in patients with rheumatoid arthritis.1 passage
• Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort.1 passage
• Low miR200b-5p levels in minor salivary glands: a novel molecular marker predicting lymphoma development in patients with Sjögren's syndrome.1 passage
• Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus.1 passage
• Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort.1 passage
• Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.1 passage
• Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study.1 passage
• Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up.1 passage
• Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences.1 passage
• Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:1 passage
• Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.1 passage
• Lupus high-density lipoprotein induces proinflammatory responses in macrophages by binding lectin-like oxidised low-density lipoprotein receptor 1 and failing to promote activating transcription factor 3 activity.1 passage
• Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.1 passage
• Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal.1 passage
• Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus.1 passage
• Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated.1 passage
• Lysosome-associated membrane protein 3 misexpression in salivary glands induces a Sjögren's syndrome-like phenotype in mice.1 passage
• METTL3-mediated m1 passage
• MICL controls inflammation in rheumatoid arthritis.1 passage
• MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.1 passage
• MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK Biobank.1 passage
• MRI assessment of early response to certolizumab pegol in rheumatoid arthritis: a randomised, double-blind, placebo-controlled phase IIIb study applying MRI at weeks 0, 1, 2, 4, 8 and 16.1 passage
• MRI assessment of suppression of structural damage in patients with rheumatoid arthritis receiving rituximab: results from the randomised, placebo-controlled, double-blind RA-SCORE study.1 passage
• MRI findings predict radiographic progression and development of erosions in hand osteoarthritis.1 passage
• MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis.1 passage
• MRI lesions in the sacroiliac joints of patients with spondyloarthritis: an update of definitions and validation by the ASAS MRI working group.1 passage
• MRI of sacroiliac joints for the diagnosis of axial SpA: prevalence of inflammatory and structural lesions in nulliparous, early postpartum and late postpartum women.1 passage
• MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis.1 passage
• MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.1 passage
• Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis.1 passage
• Machine learning identifies an immunological pattern associated with multiple juvenile idiopathic arthritis subtypes.1 passage
• Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.1 passage
• Machine learning predicts stem cell transplant response in severe scleroderma.1 passage
• Machine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative.1 passage
• Magnetic resonance imaging assessed inflammation in the wrist is associated with patient-reported physical impairment, global assessment of disease activity and pain in early rheumatoid arthritis: longitudinal results from two randomised controlled trials.1 passage
• Maintaining musculoskeletal health using a behavioural therapy approach: a population-based randomised controlled trial (the MAmMOTH Study).1 passage
• Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.1 passage
• Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.1 passage
• Management of antiphospholipid syndrome.1 passage
• Mapping and predicting mortality from systemic sclerosis.1 passage
• Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21.1 passage
• Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production.1 passage
• Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis.1 passage
• Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).1 passage
• Mechanosensitive TRPV4 is required for crystal-induced inflammation.1 passage
• Medications associated with fracture risk in patients with rheumatoid arthritis.1 passage
• Message from the new EULAR President and Steering Group.1 passage
• Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus.1 passage
• Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis.1 passage
• Metabolic pathways and immunometabolism in rare kidney diseases.1 passage
• Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population.1 passage
• Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese.1 passage
• Metformin limits osteoarthritis development and progression through activation of AMPK signalling.1 passage
• Methotrexate and BAFF interaction prevents immunization against TNF inhibitors.1 passage
• Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review.1 passage
• Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.1 passage
• Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.1 passage
• Methotrexate limits inflammation through an A20-dependent cross-tolerance mechanism.1 passage
• Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in juvenile idiopathic arthritis patients.1 passage
• Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis.1 passage
• Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis.1 passage
• Methotrexate-mediated activation of an AMPK-CREB-dependent pathway: a novel mechanism for vascular protection in chronic systemic inflammation.1 passage
• MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis.1 passage
• MicroRNA-124 inhibits the progression of adjuvant-induced arthritis in rats.1 passage
• Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation.1 passage
• Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis.1 passage
• Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.1 passage
• Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis.1 passage
• Mitochondrial DNA haplogroups influence the risk of incident knee osteoarthritis in OAI and CHECK cohorts. A meta-analysis and functional study.1 passage
• Mitochondrial genetic variation and gout in Māori and Pacific people living in Aotearoa New Zealand.1 passage
• Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis.1 passage
• Modern treatment approach results in low disease activity in 90% of pregnant rheumatoid arthritis patients: the PreCARA study.1 passage
• Modification of structural lesions on MRI of the sacroiliac joints by etanercept in the EMBARK trial: a 12-week randomised placebo-controlled trial in patients with non-radiographic axial spondyloarthritis.1 passage
• Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis.1 passage
• Molecular basis for increased susceptibility of Indigenous North Americans to seropositive rheumatoid arthritis.1 passage
• Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing.1 passage
• Molecular profile and proangiogenic activity of the adipose-derived stromal vascular fraction used as an autologous innovative medicinal product in patients with systemic sclerosis.1 passage
• Molecular signature characterisation of different inflammatory phenotypes of systemic juvenile idiopathic arthritis.1 passage
• Monocyte alterations in rheumatoid arthritis are dominated by preterm release from bone marrow and prominent triggering in the joint.1 passage
• Monocyte and bone marrow macrophage transcriptional phenotypes in systemic juvenile idiopathic arthritis reveal TRIM8 as a mediator of IFN-γ hyper-responsiveness and risk for macrophage activation syndrome.1 passage
• Monocyte and macrophage phenotypes: a look beyond systemic sclerosis. Response to: 'M1/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis' by Lescoat1 passage
• Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use.1 passage
• Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.1 passage
• Mortality following new-onset Rheumatoid Arthritis: has modern Rheumatology had an impact?1 passage
• Mortality has improved in RA, but we must remain vigilant. Response to: 'Early intensive treatment normalises excess mortality in ACPA-negative RA but not in ACPA-positive RA' by Matthijssen1 passage
• Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies.1 passage
• Mortality in ankylosing spondylitis: results from a nationwide population-based study.1 passage
• Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study.1 passage
• Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.1 passage
• Multi-OMICS analyses unveil1 passage
• Multi-dimensional analysis identified rheumatoid arthritis-driving pathway in human T cell.1 passage
• Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.1 passage
• Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus.1 passage
• Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.1 passage
• Multiomic disease signatures converge to cytotoxic CD8 T cells in primary Sjögren's syndrome.1 passage
• Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial.1 passage
• Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones1 passage
• Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.1 passage
• Myeloid-derived suppressor cells have a proinflammatory role in the pathogenesis of autoimmune arthritis.1 passage
• NAMPT (visfatin), a direct target of hypoxia-inducible factor-2α, is an essential catabolic regulator of osteoarthritis.1 passage
• NCF1-339 polymorphism is associated with altered formation of neutrophil extracellular traps, high serum interferon activity and antiphospholipid syndrome in systemic lupus erythematosus.1 passage
• NFIL3 mutations alter immune homeostasis and sensitise for arthritis pathology.1 passage
• Native joint infections in Iceland 2003-2017: an increase in postarthroscopic infections.1 passage
• Natural killer cells and type II interferon in Ro/SSA and La/SSB autoantibody-exposed newborns at risk of congenital heart block.1 passage
• Need for consensus guidelines to standardise the assessment of germinal centres and other histopathological parameters in salivary gland tissue of patients with primary Sjögren's syndrome.1 passage
• Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach.1 passage
• Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus.1 passage
• Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome.1 passage
• Neutrophil extracellular traps induce endothelial dysfunction in systemic lupus erythematosus through the activation of matrix metalloproteinase-2.1 passage
• Neutrophil extracellular traps regulate IL-1β-mediated inflammation in familial Mediterranean fever.1 passage
• Neutrophil microvesicles resolve gout by inhibiting C5a-mediated priming of the inflammasome.1 passage
• New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion.1 passage
• New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE.1 passage
• New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis.1 passage
• Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases.1 passage
• Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.1 passage
• Nitrosative modifications of the Ca2+ release complex and actin underlie arthritis-induced muscle weakness.1 passage
• No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?1 passage
• Non-response to rituximab therapy in rheumatoid arthritis is associated with incomplete disruption of the B cell receptor repertoire.1 passage
• Non-steroidal anti-inflammatory drugs for spinal pain: a systematic review and meta-analysis.1 passage
• Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: 'Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)' by Giollo1 passage
• Non-surgical and surgical treatments for rotator cuff disease: a pragmatic randomised clinical trial with 2-year follow-up after initial rehabilitation.1 passage
• Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression.1 passage
• Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up.1 passage
• Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology.1 passage
• Novel algorithms for the pragmatic use of ultrasound in the management of patients with rheumatoid arthritis: from diagnosis to remission.1 passage
• Novel and reliable DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis.1 passage
• Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis.1 passage
• Novel autoantibodies identified in ACPA-negative rheumatoid arthritis.1 passage
• Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis.1 passage
• Novel self-amplificatory loop between T cells and tenocytes as a driver of chronicity in tendon disease.1 passage
• Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?1 passage
• Novel ultrasonographic Halo Score for giant cell arteritis: assessment of diagnostic accuracy and association with ocular ischaemia.1 passage
• Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells.1 passage
• Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis.1 passage
• OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.1 passage
• Obesity and rates of clinical remission and low MRI inflammation in rheumatoid arthritis.1 passage
• Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis.1 passage
• Occupational exposure to textile dust increases the risk of rheumatoid arthritis: results from a Malaysian population-based case-control study.1 passage
• Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study.1 passage
• Omega-3 fatty acids are associated with a lower prevalence of autoantibodies in shared epitope-positive subjects at risk for rheumatoid arthritis.1 passage
• On how to not misuse hierarchical clustering on principal components to define clinically meaningful patient subgroups. Response to: 'On using machine learning algorithms to define clinical meaningful patient subgroups' by Pinal-Fernandez and Mammen.1 passage
• On the HUNT for cardiovascular risk factors and disease in patients with psoriatic arthritis: population-based data from the Nord-Trøndelag Health Study.1 passage
• On the presence of HLA-SE alleles and ACPA-IgG variable domain glycosylation in the phase preceding the development of rheumatoid arthritis.1 passage
• Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care.1 passage
• Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.1 passage
• Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.1 passage
• Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.1 passage
• Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point.1 passage
• Oral contraceptives, breastfeeding and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study.1 passage
• Organ damage in patients treated with belimumab versus standard of care: a propensity score-matched comparative analysis.1 passage
• Osteoarthritic bone marrow lesions almost exclusively colocate with denuded cartilage: a 3D study using data from the Osteoarthritis Initiative.1 passage
• Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register.1 passage
• Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.1 passage
• Outcomes of percutaneous coronary intervention in patients with rheumatoid arthritis and systemic lupus erythematosus: an 11-year nationwide cohort study.1 passage
• Overdiagnosis and overtreatment in rheumatology: a little caution is in order.1 passage
• Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome.1 passage
• PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis.1 passage
• PLD4 is a genetic determinant to systemic lupus erythematosus and involved in murine autoimmune phenotypes.1 passage
• PPARβ/δ directs the therapeutic potential of mesenchymal stem cells in arthritis.1 passage
• PPARγ preservation via promoter demethylation alleviates osteoarthritis in mice.1 passage
• PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes.1 passage
• PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.1 passage
• PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.1 passage
• PXK locus in systemic lupus erythematosus: fine mapping and functional analysis reveals novel susceptibility gene ABHD6.1 passage
• Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort.1 passage
• Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women.1 passage
• Pan PPAR agonist IVA337 is effective in prevention and treatment of experimental skin fibrosis.1 passage
• Paracetamol: not as safe as we thought? A systematic literature review of observational studies.1 passage
• Paradoxical gastrointestinal effects of interleukin-17 blockers.1 passage
• Parental rheumatoid arthritis and long-term child morbidity: a nationwide cohort study.1 passage
• Pathogenic1 passage
• Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.1 passage
• Patient organisation-led initiatives can play an important role in raising awareness about Raynaud's phenomenon and encourage earlier healthcare utilisation for high-risk groups.1 passage
• Patient preferences for psychological support in inflammatory arthritis: a multicentre survey.1 passage
• Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: the DESIR cohort.1 passage
• Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.1 passage
• Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON).1 passage
• Patients with ankylosing spondylitis have been breast fed less often than healthy controls: a case-control retrospective study.1 passage
• Patients with chronic back pain of short duration from the SPACE cohort: which MRI structural lesions in the sacroiliac joints and inflammatory and structural lesions in the spine are most specific for axial spondyloarthritis?1 passage
• Patients with gout have short telomeres compared with healthy participants: association of telomere length with flare frequency and cardiovascular disease in gout.1 passage
• Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries.1 passage
• Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.1 passage
• Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: 'Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Carbillon1 passage
• Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study.1 passage
• Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study.1 passage
• Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17.1 passage
• Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies.1 passage
• Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR/EULAR classification of rheumatoid arthritis.1 passage
• Performance of classification criteria for gout in early and established disease.1 passage
• Performance of four current risk algorithms in predicting cardiovascular events in patients with early rheumatoid arthritis.1 passage
• Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.1 passage
• Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis.1 passage
• Persistence of subclinical sonographic joint activity in rheumatoid arthritis in sustained clinical remission.1 passage
• Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.1 passage
• Persons with chronic widespread pain experience excess mortality: longitudinal results from UK Biobank and meta-analysis.1 passage
• Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).1 passage
• Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis.1 passage
• Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.1 passage
• Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial.1 passage
• Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.1 passage
• Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis.1 passage
• Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.1 passage
• Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa.1 passage
• Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis.1 passage
• Plasmablasts as a biomarker for IgG4-related disease, independent of serum IgG4 concentrations.1 passage
• Pleiotropic roles of metallothioneins as regulators of chondrocyte apoptosis and catabolic and anabolic pathways during osteoarthritis pathogenesis.1 passage
• Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative.1 passage
• Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.1 passage
• Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.1 passage
• Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.1 passage
• Poorly controlled type 2 diabetes mellitus is associated with a decreased risk of incident gout: a population-based case-control study.1 passage
• Population characteristics as important contextual factors in rheumatological trials: an exploratory meta-epidemiological study from an OMERACT Working Group.1 passage
• Position 97 of HLA-B, a residue implicated in pathogenesis of ankylosing spondylitis, plays a key role in cell surface free heavy chain expression.1 passage
• Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial.1 passage
• Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.1 passage
• Precise targeting of miR-141/200c cluster in chondrocytes attenuates osteoarthritis development.1 passage
• Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.1 passage
• Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.1 passage
• Predicting the 10-year risk of hip and major osteoporotic fracture in rheumatoid arthritis and in the general population: an independent validation and update of UK FRAX without bone mineral density.1 passage
• Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study.1 passage
• Predicting the severity of joint damage in rheumatoid arthritis; the contribution of genetic factors.1 passage
• Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.1 passage
• Prediction of cardiovascular risk in rheumatoid arthritis: performance of original and adapted SCORE algorithms.1 passage
• Prediction of disease relapses by multibiomarker disease activity and autoantibody status in patients with rheumatoid arthritis on tapering DMARD treatment.1 passage
• Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.1 passage
• Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.1 passage
• Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.1 passage
• Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study.1 passage
• Predictive factors of pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.1 passage
• Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry.1 passage
• Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA Biomarkers Consortium.1 passage
• Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.1 passage
• Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate.1 passage
• Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.1 passage
• Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis: a nationwide cohort study using Danish healthcare registers.1 passage
• Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?1 passage
• Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis.1 passage
• Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.1 passage
• Pregnancy outcomes in patients with ankylosing spondylitis: a nationwide register study.1 passage
• Preliminary definitions of 'flare' in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative.1 passage
• Preliminary predictive criteria for COVID-19 cytokine storm.1 passage
• Premature senescence of T-cell subsets in axial spondyloarthritis.1 passage
• Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands.1 passage
• Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.1 passage
• Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort.1 passage
• Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.1 passage
• Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort.1 passage
• Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.1 passage
• Prevalence and incidence rates of psoriatic arthritis in central Norway: data from the Nord-Trøndelag health study (HUNT).1 passage
• Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: 'COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs' by Conticini1 passage
• Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study.1 passage
• Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis.1 passage
• Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.1 passage
• Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.1 passage
• Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort.1 passage
• Prevalence of ultrasound synovial inflammatory findings in healthy subjects.1 passage
• Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland.1 passage
• Private rare deletions in SEC16A and MAMDC4 may represent novel pathogenic variants in familial axial spondyloarthritis.1 passage
• Progranulin protects against osteoarthritis through interacting with TNF-α and β-Catenin signalling.1 passage
• Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database.1 passage
• Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.1 passage
• Prolonged remission in Caucasian patients with SLE: prevalence and outcomes.1 passage
• Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids.1 passage
• Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.1 passage
• Prospective MRI score to predict negative EULAR response in patients with rheumatoid arthritis (RA) before therapy-escalation to a biological therapy.1 passage
• Protective effect of HLA-DRB1*13 alleles during specific phases in the development of ACPA-positive RA.1 passage
• Protein kinases G are essential downstream mediators of the antifibrotic effects of sGC stimulators.1 passage
• Proteinase-activated receptor 2 modulates OA-related pain, cartilage and bone pathology.1 passage
• Proteomic, biomechanical and functional analyses define neutrophil heterogeneity in systemic lupus erythematosus.1 passage
• Psoriasis, psoriatic arthritis and risk of gout in US men and women.1 passage
• Psoriatic arthritis treatment and the risk of herpes zoster.1 passage
• Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients.1 passage
• Quality indicators for the primary care of osteoarthritis: a systematic review.1 passage
• Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate.2 passages
• Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT.1 passage
• Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis.1 passage
• Quantitative syndesmophyte measurement in ankylosing spondylitis using CT: longitudinal validity and sensitivity to change over 2 years.1 passage
• REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A).1 passage
• RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage.1 passage
• Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study.1 passage
• Radiographic endophenotyping in hip osteoarthritis improves the precision of genetic association analysis.1 passage
• Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis.1 passage
• Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.1 passage
• Reactive arthritis and other musculoskeletal symptoms associated with acquisition of diarrhoeagenic1 passage
• Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.1 passage
• Real-world evidence of TNF inhibition in axial spondyloarthritis: can we generalise the results from clinical trials?1 passage
• Recent infections are associated with decreased risk of rheumatoid arthritis: a population-based case-control study.1 passage
• Recommendations for collaborative paediatric research including biobanking in Europe: a Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) initiative.1 passage
• Recommendations for the management of autoinflammatory diseases.1 passage
• Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT).1 passage
• Reference intervals of spinal mobility measures in normal individuals: the MOBILITY study.1 passage
• Reflecting on the global burden of musculoskeletal conditions: lessons learnt from the global burden of disease 2010 study and the next steps forward.1 passage
• Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors.1 passage
• Regulatory T cells in rheumatoid arthritis showed increased plasticity toward Th17 but retained suppressive function in peripheral blood.1 passage
• Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis.1 passage
• Relapse rates in patients with rheumatoid arthritis in stable remission tapering or stopping antirheumatic therapy: interim results from the prospective randomised controlled RETRO study.1 passage
• Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.1 passage
• Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.1 passage
• Relationship between radiographic joint space narrowing, sonographic cartilage thickness and anatomy in rheumatoid arthritis and control joints.1 passage
• Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis.1 passage
• Relationship between structural joint damage and urate deposition in gout: a plain radiography and dual-energy CT study.1 passage
• Relationship of patient-reported outcomes with MRI measures in rheumatoid arthritis.1 passage
• Reliability of a consensus-based ultrasound definition and scoring for enthesitis in spondyloarthritis and psoriatic arthritis: an OMERACT US initiative.1 passage
• Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL).1 passage
• Remission in systemic lupus erythematosus: durable remission is rare.1 passage
• Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort.1 passage
• Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.1 passage
• Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles.1 passage
• Response to 'Application of MS score in macrophage activation syndrome patients associated with adult onset Still's disease' by Wang1 passage
• Response to 'Correspondence on 'Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort' by Ruyssen-Witrand1 passage
• Response to 'Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier' by Alunno1 passage
• Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis.1 passage
• Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro1 passage
• Response to: ' "Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers' effectiveness in axial spondyloarthritis: results of a prospective, multicentre study" by Moltó1 passage
• Response to: '2016 update of the EULAR recommendations for the management of rheumatoid arthritis: no utopia for patients in low/middle-income countries?' by Misra1 passage
• Response to: 'A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease' by Aeschlimann1 passage
• Response to: 'Achieving lupus low disease activity and remission states under belimumab in refractory systemic lupuserythematosus: time and organ involvement matter' by Sbeih1 passage
• Response to: 'Additional proposals to reduce comorbidity in patients with chronic inflammatory rheumatic diseases'. Screening for comorbidities: what is the remit of rheumatologists?1 passage
• Response to: 'Antinuclear antibody as entry criterion for classification of systemic lupus erythematosus: pitfalls and opportunities' by Bossuyt1 passage
• Response to: 'Association between use of non-steroidal anti-inflammatory drugs and risk of myocardial infarction in patients with spondyloarthritis and osteoarthritis'.1 passage
• Response to: 'Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou1 passage
• Response to: 'Clarification regarding the statement of the association between the recombinant zoster vaccine (RZV) and gout flares' by Didierlaurent1 passage
• Response to: 'Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease' by Orlando1 passage
• Response to: 'Comment on 'Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab'' by Pethoe-Schramm1 passage
• Response to: 'Comment on 'Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial' by Tanaka1 passage
• Response to: 'Comment on: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S1 passage
• Response to: 'Comment on: 'Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria' by Greco1 passage
• Response to: 'Comment on: 'Lupus Low Disease Activity State(LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hocanalysis of the Phase IIb MUSE trial of anifrolumab' by Eric Morand et al' by Isenberg.1 passage
• Response to: 'Comments on the article: "Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial"' by Mousavi and Taherifard.1 passage
• Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus' by Rua-Figueroa and Erausquin.1 passage
• Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.1 passage
• Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli1 passage
• Response to: 'Correspondence on 'Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries' by Nokhatha1 passage
• Response to: 'Correspondence on 'SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists'' by Smerilli1 passage
• Response to: 'Correspondence on Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab' by Messina1 passage
• Response to: 'Correspondence to: 'Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis'' by Ma1 passage
• Response to: 'Could autologous adipose-derived stromal vascular fraction turn out an unwanted source of profibrotic myofibroblasts in systemic sclerosis?' by Manetti.1 passage
• Response to: 'Does it make sense to investigate whether the offspring of people with a total knee replacement for severe primary knee osteoarthritis have a higher risk of worsening knee pain?' by Lei et al.1 passage
• Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.1 passage
• Response to: 'Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1' by Michot et al and 'Checkpoint inhibitor-associated immune arthritis' by Arnaud1 passage
• Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.1 passage
• Response to: 'Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) induced by immune checkpoint inhibitors' by Delyon1 passage
• Response to: 'European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view' by Infantino1 passage
• Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo1 passage
• Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials' by Lee and Song.1 passage
• Response to: 'In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?' by Manetti and Matucci-Cerinic.1 passage
• Response to: 'Is it currently reasonable to offer short 14-day antibiotic therapies after a surgical synovectomy in native joint septic arthritis?' by Coiffier1 passage
• Response to: 'Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry' by Favalli et al.1 passage
• Response to: 'Monocyte type I interferon signature in antiphospholipid syndrome is related to pro-inflammatory monocyte subsets, hydroxychloroquine and statin use' by van den Hoogen et al.1 passage
• Response to: 'Mycophenolate mofetil: a step forward in the induction treatment of ANCA-associated vasculitis? Comment on the article by Jones1 passage
• Response to: 'Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki1 passage
• Response to: 'Neutrophil extracellular traps and low-density granulocytes are associated with the interferon signature in systemic lupus erythematosus, but not in antiphospholipid syndrome' by van den Hoogen1 passage
• Response to: 'New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion' by Sacre1 passage
• Response to: 'OCTA, a sensitive screening for asymptomatic retinopathy, raises alarm over systemic involvements in patients with SLE' by Mizuno et1 passage
• Response to: 'Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23 years follow-up of a population-based cohort of middle-aged women' by Gao et al.1 passage
• Response to: 'Patients with lupus are not protected from COVID-19: a comment' by Sawalha, 'No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit' by Romão1 passage
• Response to: 'Pitfalls of antinuclear antibody detection in systemic lupus erythematosus: the positive experience of a national multi-center study' by Pregnalato1 passage
• Response to: 'Prevention of infections in patients with antineutrophil cytoplasm antibody-associated vasculitis: potential role of hydroxychloroquine' by Novikov1 passage
• Response to: 'Regulatory T cell frequencies in patients with rheumatoid arthritis are increased by conventional and biological DMARDs but not by JAK inhibitors' by Meyer1 passage
• Response to: 'Response to: "Influence of changes in cholesterol levels and disease activity on the 10-year cardiovascular risk estimated with different algorithms in rheumatoid arthritis patients" by Fornaro1 passage
• Response to: 'Revised 2017 international consensus on ANCA testing in small vessel vasculitis: support from an external quality assessment' by Broeders1 passage
• Response to: 'Risk of severe infection following rituximab and the efficacy of antimicrobial prophylaxis' by Wallace1 passage
• Response to: 'Role of tubulointerstitial injury in ANCA-associated vasculitis is underestimated' by Moiseev1 passage
• Response to: 'Statin therapy now more common than steroids in clinical practice' by Pareek and Chankurdar.1 passage
• Response to: 'Switching from the bio-originators to biosimilar: is it premature to recommend this procedure?' by Cantini and Benucci.1 passage
• Response to: 'Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients' by Buch1 passage
• Response to: 'Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from the STRASS study' by Marotte1 passage
• Response to: 'The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus' by Zhang1 passage
• Response to: 'The time has come to revisit alternative interpretations of data underlying the EULAR management recommendations for rheumatoid arthritis' by Pirilä1 passage
• Response to: 'Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?' by Coiffier1 passage
• Response to: 'Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?' by Coiffier1 passage
• Response to: Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis by Kremer and Weinblatt.1 passage
• Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis.1 passage
• Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.1 passage
• Revised 2017 international consensus on ANCA testing in small vessel vasculitis: support from an external quality assessment.1 passage
• Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.1 passage
• Revisiting comorbidities in gout: a cluster analysis.1 passage
• Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previously immunised with 23-valent pneumococcal polysaccharide vaccine.1 passage
• Revisiting the use of remission criteria for rheumatoid arthritis by excluding patient global assessment: an individual meta-analysis of 5792 patients.1 passage
• Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.1 passage
• Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.1 passage
• Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present.1 passage
• Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood.1 passage
• Rheumatoid arthritis-associated DNA methylation sites in peripheral blood mononuclear cells.1 passage
• Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2.1 passage
• Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial.1 passage
• Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study.1 passage
• Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.1 passage
• Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations.1 passage
• Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases.1 passage
• Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.1 passage
• Risk of breast cancer before and after rheumatoid arthritis, and the impact of hormonal factors.1 passage
• Risk of cardiac rhythm disturbances and aortic regurgitation in different spondyloarthritis subtypes in comparison with general population: a register-based study from Sweden.1 passage
• Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.1 passage
• Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.1 passage
• Risk of gout flares after vaccination: a prospective case cross-over study.1 passage
• Risk of herpes zoster (shingles) in patients with rheumatoid arthritis under biologic, targeted synthetic and conventional synthetic DMARD treatment: data from the German RABBIT register.1 passage
• Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study.1 passage
• Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy.1 passage
• Risk of incident atrial fibrillation in gout: a cohort study.1 passage
• Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers.1 passage
• Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.1 passage
• Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.1 passage
• Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.1 passage
• Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors.1 passage
• Risk of myocardial infarction with use of selected non-steroidal anti-inflammatory drugs in patients with spondyloarthritis and osteoarthritis.1 passage
• Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden.1 passage
• Risk of preterm delivery and small-for-gestational-age births in women with autoimmune disease using biologics before or during pregnancy: a population-based cohort study.1 passage
• Risk of second malignant neoplasm and mortality in patients with rheumatoid arthritis treated with biological DMARDs: a Danish population-based cohort study.1 passage
• Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden.1 passage
• Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.1 passage
• Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan.1 passage
• Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.1 passage
• Risk of systemic lupus erythematosus in patients with idiopathic thrombocytopenic purpura: a population-based cohort study.1 passage
• Risk of uveitis and inflammatory bowel disease in people with psoriatic arthritis: a population-based cohort study.1 passage
• Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study.1 passage
• Risk of venous thromboembolism in knee, hip and hand osteoarthritis: a general population-based cohort study.1 passage
• Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden.1 passage
• Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.1 passage
• Rituximab for IgG4-related disease: a prospective, open-label trial.1 passage
• Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss).1 passage
• Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.1 passage
• Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.1 passage
• Role of erosions typical of rheumatoid arthritis in the 2010 ACR/EULAR rheumatoid arthritis classification criteria: results from a very early arthritis cohort.1 passage
• Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis.1 passage
• Role of miR-146a in regulation of the acute inflammatory response to monosodium urate crystals.1 passage
• Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia.1 passage
• Role of vascular channels as a novel mechanism for subchondral bone damage at cruciate ligament entheses in osteoarthritis and inflammatory arthritis.1 passage
• Running promotes chronicity of arthritis by local modulation of complement activators and impairing T regulatory feedback loops.1 passage
• SAMHD1 prevents autoimmunity by maintaining genome stability.1 passage
• SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.1 passage
• SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.1 passage
• Sacroiliac radiographic progression in recent onset axial spondyloarthritis: the 5-year data of the DESIR cohort.1 passage
• Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.1 passage
• Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.1 passage
• Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trial.1 passage
• Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.1 passage
• Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).1 passage
• Safety and immune response of a live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a randomised placebo-controlled trial.1 passage
• Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial.1 passage
• Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.1 passage
• Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.1 passage
• Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis.1 passage
• Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.1 passage
• Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study.1 passage
• Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial.1 passage
• Salivary gland epithelial cells from patients with Sjögren's syndrome induce B-lymphocyte survival and activation.1 passage
• Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN).1 passage
• Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor.1 passage
• Scoring hypoechogenic areas in one parotid and one submandibular gland increases feasibility of ultrasound in primary Sjögren's syndrome.1 passage
• Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.1 passage
• Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.1 passage
• Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1).1 passage
• Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial.1 passage
• Self-management approaches for osteoarthritis in the hand: a 2×2 factorial randomised trial.1 passage
• Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis.1 passage
• Sensitivity and sensitisation in relation to pain severity in knee osteoarthritis: trait or state?1 passage
• Separately tackling the development of erosions with denosumab: ultimately closing a gap in the treatment of patients with rheumatoid arthritis or trying too hard too late?1 passage
• Sequencing of the MHC region defines1 passage
• Serious adverse events and the risk of stroke in patients with rheumatoid arthritis: results from the German RABBIT cohort.1 passage
• Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.1 passage
• Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study.1 passage
• Serum NT/CT SIRT1 ratio reflects early osteoarthritis and chondrosenescence.1 passage
• Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan.1 passage
• Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis.1 passage
• Seven-year tolerability profile of glucocorticoids use in early rheumatoid arthritis: data from the ESPOIR cohort.1 passage
• Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles.1 passage
• Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients.1 passage
• Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations.1 passage
• Shared epitope defines distinct associations of cigarette smoking with levels of anticitrullinated protein antibody and rheumatoid factor.1 passage
• Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation.1 passage
• Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials.1 passage
• Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis.1 passage
• Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.1 passage
• Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in ankylosing spondylitis patients, as well as the effects of TNFi therapy upon microbiome composition.1 passage
• Should 2016 Criteria for Macrophage Activation Syndrome be applied in children with Kawasaki disease, as well as with systemic-onset juvenile idiopathic arthritis?1 passage
• Sialendoscopy enhances salivary gland function in Sjögren's syndrome: a 6-month follow-up, randomised and controlled, single blind study.1 passage
• Siblings of patients with rheumatoid arthritis are at increased risk of acute coronary syndrome.1 passage
• Sicca: an important manifestation of damage in systemic sclerosis (SSc) and SSc-overlap syndromes. Response to 'Do the salivary glands of patients with systemic sclerosis show ultrasonographic modifications suggestive of Sjögren's syndrome?' by Coudrec1 passage
• Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.1 passage
• Signal intensity alteration in the infrapatellar fat pad at baseline for the prediction of knee symptoms and structure in older adults: a cohort study.1 passage
• Signature of circulating microRNAs in osteoarthritis.1 passage
• Significance of structural changes in the sacroiliac joints of patients with axial spondyloarthritis detected by MRI related to patients symptoms and functioning.1 passage
• Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis.1 passage
• Signs of immune activation and local inflammation are present in the bronchial tissue of patients with untreated early rheumatoid arthritis.1 passage
• Silencing or inhibition of endoplasmic reticulum aminopeptidase 1 (ERAP1) suppresses free heavy chain expression and Th17 responses in ankylosing spondylitis.1 passage
• Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.1 passage
• Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs.1 passage
• Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration.1 passage
• Single-cell RNA-seq analysis reveals the progression of human osteoarthritis.1 passage
• Single-cell analysis reveals fibroblast heterogeneity and myofibroblasts in systemic sclerosis-associated interstitial lung disease.1 passage
• Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis.1 passage
• Sirt1 regulates canonical TGF-β signalling to control fibroblast activation and tissue fibrosis.1 passage
• Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.1 passage
• Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis.1 passage
• Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study.1 passage
• Social media use among young rheumatologists and basic scientists: results of an international survey by the Emerging EULAR Network (EMEUNET).1 passage
• Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study.1 passage
• Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.1 passage
• Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra.1 passage
• Somatic NLRP3 mosaicism in Muckle-Wells syndrome. A genetic mechanism shared by different phenotypes of cryopyrin-associated periodic syndromes.1 passage
• Spatial distribution of syndesmophytes along the vertebral rim in ankylosing spondylitis: preferential involvement of the posterolateral rim.1 passage
• Specific changes in faecal microbiota are associated with familial Mediterranean fever.1 passage
• Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project.1 passage
• Splicing machinery is impaired in rheumatoid arthritis, associated with disease activity and modulated by anti-TNF therapy.1 passage
• Splicing variant of1 passage
• Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome.1 passage
• Standardisation of the detection of germinal centres in salivary gland biopsies of patients with primary Sjögren's syndrome is needed to assess their clinical relevance.1 passage
• Statin use and mortality in rheumatoid arthritis: a general population-based cohort study.1 passage
• Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study).1 passage
• Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study.1 passage
• Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie1 passage
• Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.1 passage
• Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage.1 passage
• Stroke in systemic lupus erythematosus: a Swedish population-based cohort study.1 passage
• Subclinical joint inflammation in patients with psoriasis without concomitant psoriatic arthritis: a cross-sectional and longitudinal analysis.1 passage
• Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.1 passage
• Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.1 passage
• Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.1 passage
• Subtype-specific gout susceptibility loci and enrichment of selection pressure on1 passage
• Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial.1 passage
• Successful treatment of arthritis induced by checkpoint inhibitors with tocilizumab: a case series.1 passage
• Suitability Of Nitisinone In Alkaptonuria 1 (SONIA 1): an international, multicentre, randomised, open-label, no-treatment controlled, parallel-group, dose-response study to investigate the effect of once daily nitisinone on 24-h urinary homogentisic acid excretion in patients with alkaptonuria after 4 weeks of treatment.1 passage
• Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases.1 passage
• Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study.1 passage
• Survival benefit of statin use in ankylosing spondylitis: a general population-based cohort study.1 passage
• Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016.1 passage
• Sustained discontinuation of infliximab with a raising-dose strategy after obtaining remission in patients with rheumatoid arthritis: the RRRR study, a randomised controlled trial.1 passage
• Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.1 passage
• Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.1 passage
• Swollen, but not tender joints, are independently associated with ultrasound synovitis: results from a longitudinal observational study of patients with established rheumatoid arthritis.1 passage
• Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis.1 passage
• Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients.1 passage
• Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?1 passage
• Synovial fluid hyaluronan mediates MSC attachment to cartilage, a potential novel mechanism contributing to cartilage repair in osteoarthritis using knee joint distraction.1 passage
• Synovial fluid mononuclear cells provide an environment for long-term survival of antibody-secreting cells and promote the spontaneous production of anti-citrullinated protein antibodies.1 passage
• Synovial macrophage M1 polarisation exacerbates experimental osteoarthritis partially through R-spondin-2.1 passage
• Synovial tissue signatures enhance clinical classification and prognostic/treatment response algorithms in early inflammatory arthritis and predict requirement for subsequent biological therapy: results from the pathobiology of early arthritis cohort (PEAC).1 passage
• Synovial tissue volume: a treatment target in knee osteoarthritis (OA).1 passage
• Synovitis in knee osteoarthritis: a precursor of disease?1 passage
• Systematic approach demonstrates enrichment of multiple interactions between non-1 passage
• Systematic evaluation of nine monogenic autoinflammatory diseases reveals common and disease-specific correlations with allergy-associated features.1 passage
• Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity.1 passage
• Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients.1 passage
• Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study.1 passage
• Systemic inflammation and cardiovascular risk factors predict rapid progression of atherosclerosis in rheumatoid arthritis.1 passage
• Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.1 passage
• Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management.1 passage
• T cell receptor β repertoires as novel diagnostic markers for systemic lupus erythematosus and rheumatoid arthritis.1 passage
• T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individuals.1 passage
• TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis.1 passage
• TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.1 passage
• TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.1 passage
• TGFβ responsive tyrosine phosphatase promotes rheumatoid synovial fibroblast invasiveness.1 passage
• TLR41 passage
• TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.1 passage
• TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study.1 passage
• TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis.1 passage
• TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis.1 passage
• TRIM24-RIP3 axis perturbation accelerates osteoarthritis pathogenesis.1 passage
• Tackling osteoarthritis during COVID-19 pandemic.1 passage
• Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.1 passage
• Takayasu arteritis risk locus in1 passage
• Tapering biologic and conventional DMARD therapy in rheumatoid arthritis: current evidence and future directions.1 passage
• Tapering conventional synthetic DMARDs in patients with early arthritis in sustained remission: 2-year follow-up of the tREACH trial.1 passage
• Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial.1 passage
• Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis.1 passage
• Targeting JAK/STAT pathway in Takayasu's arteritis.1 passage
• Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?1 passage
• Targeting human plasmacytoid dendritic cells through BDCA2 prevents skin inflammation and fibrosis in a novel xenotransplant mouse model of scleroderma.1 passage
• Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.1 passage
• Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.1 passage
• Tenascin-C-mediated suppression of extracellular matrix adhesion force promotes entheseal new bone formation through activation of Hippo signalling in ankylosing spondylitis.1 passage
• Tenosynovitis has a high sensitivity for early ACPA-positive and ACPA-negative RA: a large cross-sectional MRI study.1 passage
• Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?1 passage
• Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.1 passage
• Tetraspanin CD82 affects migration, attachment and invasion of rheumatoid arthritis synovial fibroblasts.1 passage
• The1 passage
• The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology.1 passage
• The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.1 passage
• The EULAR Outcome Measures Library: an evolutional database of validated patient-reported instruments.1 passage
• The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation.1 passage
• The EuroMyositis registry: an international collaborative tool to facilitate myositis research.1 passage
• The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index.1 passage
• The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.1 passage
• The SSB-positive/SSA-negative antibody profile is not associated with key phenotypic features of Sjögren's syndrome.1 passage
• The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis.1 passage
• The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region.1 passage
• The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor.1 passage
• The autoimmune-associated genetic variant PTPN22 R620W enhances neutrophil activation and function in patients with rheumatoid arthritis and healthy individuals.1 passage
• The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts.1 passage
• The challenge to interpret conflicting results and the need of a univocal definition for germinal centres in primary Sjögren's syndrome.1 passage
• The changing landscape of biosimilars in rheumatology.1 passage
• The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor.1 passage
• The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.1 passage
• The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.1 passage
• The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: 'Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India' by Gupta1 passage
• The diagnostic accuracy of the squeeze test to identify arthritis: a cross-sectional cohort study.1 passage
• The diagnostic utility of serum IgG4 concentrations in IgG4-related disease.1 passage
• The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.1 passage
• The earlier, the better or the worse? Towards accurate management of patients with arthralgia at risk for RA.1 passage
• The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.1 passage
• The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients.1 passage
• The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients.1 passage
• The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.1 passage
• The effects of structural damage on functional disability in psoriatic arthritis.1 passage
• The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis.1 passage
• The efficacy of motivational counselling and SMS reminders on daily sitting time in patients with rheumatoid arthritis: a randomised controlled trial.1 passage
• The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study.1 passage
• The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review.1 passage
• The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy.1 passage
• The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.1 passage
• The genetic association of RUNX3 with ankylosing spondylitis can be explained by allele-specific effects on IRF4 recruitment that alter gene expression.1 passage
• The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.1 passage
• The incidence and prevalence of systemic lupus erythematosus in the UK, 1999-2012.1 passage
• The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.1 passage
• The intervertebral disc contains intrinsic circadian clocks that are regulated by age and cytokines and linked to degeneration.1 passage
• The level of peripheral regulatory T cells is linked to changes in gut commensal microflora in patients with systemic lupus erythematosus.1 passage
• The microbiome in rheumatology: Where are we and where should we go?1 passage
• The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort.1 passage
• The offspring of people with a total knee replacement for severe primary knee osteoarthritis have a higher risk of worsening knee pain over 8 years.1 passage
• The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort.1 passage
• The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission.1 passage
• The patient perspective on remission in rheumatoid arthritis: 'You've got limits, but you're back to being you again'.1 passage
• The population prevalence of symptomatic radiographic foot osteoarthritis in community-dwelling older adults: cross-sectional findings from the clinical assessment study of the foot.1 passage
• The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study.1 passage
• The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus.1 passage
• The relative contribution of mechanical stress and systemic processes in different types of osteoarthritis: the NEO study.1 passage
• The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK.1 passage
• The risk and nature of flares in juvenile idiopathic arthritis: results from the ReACCh-Out cohort.1 passage
• The risk of deep venous thrombosis and pulmonary embolism in giant cell arteritis: a general population-based study.1 passage
• The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study.1 passage
• The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.1 passage
• The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be.1 passage
• The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease.1 passage
• The specificity of ultrasound-detected bone erosions for rheumatoid arthritis.1 passage
• The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis.1 passage
• The transcription factor GLI2 as a downstream mediator of transforming growth factor-β-induced fibroblast activation in SSc.1 passage
• The unclosing premature mortality gap in gout: a general population-based study.1 passage
• The use of MRI-detected synovitis to determine the number of involved joints for the 2010 ACR/EULAR classification criteria for Rheumatoid Arthritis - is it of additional benefit?1 passage
• The value of1 passage
• The world-wide burden of musculoskeletal diseases: a systematic analysis of the World Health Organization Burden of Diseases Database.1 passage
• The yield of a positive MRI of the spine as imaging criterion in the ASAS classification criteria for axial spondyloarthritis: results from the SPACE and DESIR cohorts.1 passage
• Therapeutic drug monitoring of adalimumab in RA: no predictive value of adalimumab serum levels and anti-adalimumab antibodies for prediction of response to the next bDMARD.1 passage
• Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.1 passage
• Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.1 passage
• Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.1 passage
• Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000-2010.1 passage
• Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review.1 passage
• Tissue physiology revolving around the clock: circadian rhythms as exemplified by the intervertebral disc.1 passage
• To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.1 passage
• Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial.1 passage
• Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study).1 passage
• Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial.1 passage
• Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.1 passage
• Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan.1 passage
• Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.1 passage
• Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.1 passage
• Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors.1 passage
• Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.1 passage
• Tolerising cellular therapies: what is their promise for autoimmune disease?1 passage
• Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies.1 passage
• Towards consensus in defining and handling contextual factors within rheumatology trials: an initial qualitative study from an OMERACT working group.1 passage
• Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment.1 passage
• Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables.1 passage
• Transcutaneous auricular vagus nerve stimulation reduces pain and fatigue in patients with systemic lupus erythematosus: a randomised, double-blind, sham-controlled pilot trial.1 passage
• Transethnic meta-analysis identifies1 passage
• Transient receptor potential canonical 5 (TRPC5) protects against pain and vascular inflammation in arthritis and joint inflammation.1 passage
• Transitions to different patterns of interstitial lung disease in scleroderma with and without treatment.1 passage
• Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.1 passage
• Treat-to-target (T2T) recommendations for gout.1 passage
• Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis.1 passage
• Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.1 passage
• Treating juvenile idiopathic arthritis to target: recommendations of an international task force.1 passage
• Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.1 passage
• Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis.1 passage
• Treating to target in psoriatic arthritis: how to implement in clinical practice.1 passage
• Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study.1 passage
• Treatment failure in giant cell arteritis.1 passage
• Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression.1 passage
• Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.1 passage
• Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS).1 passage
• Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.1 passage
• Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.1 passage
• Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis.1 passage
• Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.1 passage
• Tuberculosis in biologic users for rheumatic diseases: results from the South African Biologics Registry (SABIO).1 passage
• Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis.1 passage
• Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.1 passage
• Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence.1 passage
• Twenty-eight loci that influence serum urate levels: analysis of association with gout.1 passage
• Two weeks versus four weeks of antibiotic therapy after surgical drainage for native joint bacterial arthritis: a prospective, randomised, non-inferiority trial.1 passage
• Two-dose COVID-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.1 passage
• Two-year cost effectiveness between two gradual tapering strategies in rheumatoid arthritis: cost-utility analysis of the TARA trial.1 passage
• Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.1 passage
• Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis.1 passage
• Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis.1 passage
• Tyrosine kinase Fyn promotes osteoarthritis by activating the β-catenin pathway.1 passage
• Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis.1 passage
• Ultrasensitive serum interferon-α quantification during SLE remission identifies patients at risk for relapse.1 passage
• Ultrasonographic damages of major salivary glands are associated with cryoglobulinemic vasculitis and lymphoma in primary Sjogren's syndrome: are the ultrasonographic features of the salivary glands new prognostic markers in Sjogren's syndrome?1 passage
• Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.1 passage
• Ultrasonographic salivary gland evaluation in systemic sclerosis: is sicca syndrome secondary to an authentic overlap syndrome or another specific fibrotic manifestation of the disease?1 passage
• Ultrasonography of major salivary glands compared with parotid and labial gland biopsy and classification criteria in patients with clinically suspected primary Sjögren's syndrome.1 passage
• Ultrasound Doppler and tenosynovial fluid analysis in tenosynovitis.1 passage
• Ultrasound definition of enthesitis in spondyloarthritis and psoriatic arthritis: arrival or starting point?1 passage
• Ultrasound erosions in the feet best predict progression to inflammatory arthritis in anti-CCP positive at-risk individuals without clinical synovitis.1 passage
• Ultrasound findings predict progression to inflammatory arthritis in anti-CCP antibody-positive patients without clinical synovitis.1 passage
• Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis: a prospective analysis.1 passage
• Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study.1 passage
• Ultrasound-detected inflammation predicts radiographic progression in hand osteoarthritis after 5 years.1 passage
• Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients.1 passage
• Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis.1 passage
• Unifocal psoriatic arthritis development in identical twins following site specific injury: evidence supporting biomechanical triggering events in genetically susceptible hosts.1 passage
• Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma.1 passage
• Unique role of rheumatology in establishing collaborative relationships in research. Past, present and future of patient engagement.1 passage
• Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.1 passage
• Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.1 passage
• Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.1 passage
• Update of EULAR recommendations for the treatment of systemic sclerosis.1 passage
• Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.1 passage
• Update οn the diagnosis and management of systemic lupus erythematosus.1 passage
• Urate crystal deposition in asymptomatic hyperuricaemia and symptomatic gout: a dual energy CT study.1 passage
• Urate-lowering therapy (ULT) reduces non-episodic foot pain in patients who fail to meet ACR/EULAR 2015 gout classification criteria: an effect predicted by ultrasound and potential rationale for reclassification.1 passage
• Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study.1 passage
• Urinary epidermal growth factor predicts renal prognosis in antineutrophil cytoplasmic antibody-associated vasculitis.1 passage
• Use of multidimensional composite scores in rheumatology: parsimony versus subtlety.1 passage
• Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts.1 passage
• Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).1 passage
• Validation of a score tool for measurement of histological severity in juvenile dermatomyositis and association with clinical severity of disease.1 passage
• Validation of the 2019 ACR/EULAR criteria for IgG4-related disease in a Japanese kidney disease cohort: a multicentre retrospective study by the IgG4-related kidney disease working group of the Japanese Society of Nephrology.1 passage
• Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire.1 passage
• Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice.1 passage
• Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.1 passage
• Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.1 passage
• Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank.1 passage
• Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs.1 passage
• Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study.1 passage
• Very low prevalence of ultrasound-detected tenosynovial abnormalities in healthy subjects throughout the age range: OMERACT ultrasound minimal disease study.1 passage
• Video clip assessment of a salivary gland ultrasound scoring system in Sjögren's syndrome using consensual definitions: an OMERACT ultrasound working group reliability exercise.1 passage
• Visualisation of interstitial lung disease by molecular imaging of integrin αvβ3 and somatostatin receptor 2.1 passage
• Vitamin D receptor regulates TGF-β signalling in systemic sclerosis.1 passage
• Vitamin K antagonist anticoagulant usage is associated with increased incidence and progression of osteoarthritis.1 passage
• Warfarin use and risk of knee and hip replacements.1 passage
• Weight change and change in tibial cartilage volume and symptoms in obese adults.1 passage
• Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies.1 passage
• What are the effects of medication adherence interventions in rheumatic diseases: a systematic review.1 passage
• What constitutes the fat signal detected by MRI in the spine of patients with ankylosing spondylitis? A prospective study based on biopsies obtained during planned spinal osteotomy to correct hyperkyphosis or spinal stenosis.1 passage
• What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts.1 passage
• What is the impact of chronic systemic inflammation such as rheumatoid arthritis on mortality following cancer?1 passage
• Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease.1 passage
• Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids.1 passage
• Whole-genome single nucleotide polymorphism-based linkage analysis in spondyloarthritis multiplex families reveals a new susceptibility locus in 13q13.1 passage
• Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial.1 passage
• Wnt16 attenuates osteoarthritis progression through a PCP/JNK-mTORC1-PTHrP cascade.1 passage
• Work disability in gout: a population-based case-control study.1 passage
• Work participation in spondyloarthritis across countries: analysis from the ASAS-COMOSPA study.1 passage
• Worsening of pain and function over 5 years in individuals with 'early' OA is related to structural damage: data from the Osteoarthritis Initiative and CHECK (Cohort Hip & Cohort Knee) study.1 passage
• X-linked inhibitor of apoptosis protein (XIAP) inhibition in systemic sclerosis (SSc).1 passage
• [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis.1 passage
• circPDE4B prevents articular cartilage degeneration and promotes repair by acting as a scaffold for RIC8A and MID1.1 passage
• mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout: a prelude to a new add-on therapy?1 passage
• miR-10b-5p is a novel Th17 regulator present in Th17 cells from ankylosing spondylitis.1 passage
• microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints.1 passage